前列腺增生症与下尿路症状的临床研究
摘要
研究目的：了解成年男性下尿路症状(LUTS)的发生情况、年龄分布与变化规律,为进一步了解BPH有关LUTS的临床特点、影响因素、产生机理及治疗策略提供一些新的启发。
研究方法：采用国际前列腺症状评分问卷(IPSS)表调查前来我院进行健康体检的成年男性1048人,年龄30岁-80岁,以10岁为一年龄段,分为5个年龄段,评估被调查者的LUTS发生情况。
结果：各组LUTS发生的情况为：30岁年龄段347人,平均IPSS评分2.48±0.38；40岁年龄段311人,平均IPSS评分3.80±0.53；50岁年龄段114人,平均IPSS评分4.78±1.07；60岁年龄段207人,平均IPSS评分5.33±0.68；70岁年龄段69人,平均IPSS评分6.80±1.66。其中各年龄组储尿期症状平均评分分别为：1.20,1.66,2.24,2.57,3.20；排尿期症状平均评分分别为：1.28,2.14,2.54,2.76,3.59；生活质量平均评分为：1.78±1.42,1.84±0.30,1.89±1.04,2.03±1.08,2.07±1.92。不同年龄组男性LUTS发生率与年龄相关(χ2=70.46,P<0.005)。IPSS总评分、排尿期症状评分及储尿期症状评分与生活质量评分呈正相关,其中储尿期症状比排尿期症状对生活质量影响更大些(储尿期评分、排尿期评分与QoL评分相关系数分别为：r=0.966(P<0.05),r=0.931(P<0.05))。
结论：LUTS症状在成年健康男性中较普遍存在,发病率随年龄增大而增加。LUTS症状越重,对生活质量影响越大,而储尿期症状较排尿期症状对生活质量影响更大些。
目的：探讨前列腺增生症(BPH)患者出现下尿路症状(LUTS)的临床特点及其对患者生活质量的影响。
方法：对2003年7月至2009年10月收治的548例前列腺增生症患者的资料进行回顾性研究。分析患者住院时填写的国际前列腺症状问卷调查表(IPSS)/自行设计的夜尿症状评分表及性功能问卷调查表(MSF-4)上的数据,并对这些数据进行统计学分析。
结果：548例患者LUTS中,中度(8-19分)占24.8%,重度(20-35分)占75.2%。LUTS及其中各单个症状均与年龄存在正相关但相关性较小。LUTS及其中各单个症状与QoL正相关,症状评分越高,QoL评分也高。其中夜尿增多(NQ7)与QoL相关性最大,其次是排尿不尽(NQ1)、排尿无力(NQ5)。28.6%(157／548)的患者认为夜尿增多对自己影响最大,主要影响患者的睡眠(NQ5),其次是引起患者次日疲倦、注意力下降(NQ1)及担心影响家人或伴侣的睡眠(NQ6)。经Spearman等级相关分析发现IPSS评分与MSF-4评分存在正相关(P<0.0001),其中夜尿增多、排尿困难及尿频是影响患者性功能最大的三个尿路症状(r为0.20648、020635、0.18861)。
结论：LUTS严重地影响BPH患者的生活质量,并影响患者的性功能。应重视对BPH患者夜尿增多的研究及其对患者睡眠及生活质量的影响。
目的：探讨不同的临床因素与前列腺增生症(BPH)相关下尿路症状(LUTS)之间的关系,了解影响BPH有关LUTS的危险因素。
方法：对2003年7月至2009年10月收治的548例前列腺增生症患者的资料进行回顾性研究。分析不同年龄、病史、最大尿流率、前列腺总体积、移行区体积、移行区指数、总PSA、游总比(f/tPSA)、组织炎症对IPSS值的影响,并进行多元线性回归分析。
结果：年龄、移行带体积、Qmax、PSA及前列腺组织炎症对IPSS评分影响显著。随着年龄增大和移行带体积的增加,IPSS值变大；随着最大尿流率的减少,IPSS值显著增加(P<0.05)。当PSA≥4ng/ml时,IPSS值要显著大于<4ng/ml组的IPSS值(P<0.05),但是介于4-10ng/ml组和≥10ng/ml组的IPSS评分并无差异(P<0.05)。合并前列腺组织炎症患者的IPSS值要显著高于非炎症组(P<0.05)。进一步通过多元线性回归分析,发现所有可能影响IPSS评分的因素中,Qmax和前列腺组织炎症与IPSS评分密切相关(p=-0.807,5.736；P<0.001)。
结论：前列腺组织炎症和Qmax对下尿路症状的影响最显著。其他的临床因素如患者年龄、移行带体积和PSA值对BPH患者的下尿路症状影响有限,经过多因素回归分析发现并无显著性。
目的：急性尿储留(AUR)是一种常见的泌尿外科需要急诊处理的情况。前列腺增生症(BPH)是老年男性的一种常见疾病,是引起AUR最常见的原因之一。本研究试图探讨BPH患者发生AUR的危险因素,以便在治疗BPH患者时采取合理的预防措施。
方法：对2003年7月至2009年12月收治的548例前列腺增生症患者的资料进行回顾性研究。对患者的年龄、病程、IPSS评分、Qmax、残余尿量、前列腺体积、移行区体积、移行区指数、tPSA、fPSA、游总比及PSAD等数据进行统计学分析。
结果：548例参与调查的BPH患者中,合并AUR的患者为164例(29.9%),不伴有AUR的患者为384例(70.1%)。两组患者的年龄、IPSS评分、Qmax、残余尿量、前列腺体积、移行区体积、tPSA、fPSA、游总比及PSAD有显著差异(P<0.05),而两组间的病程和移行区指数无显著性差异。进一步多因素Logistic回归分析显示,IPSS、残余尿量、tPSA及Qmax是AUR发生最相关的因素。
结论：BPH患者的年龄、IPSS评分、Qmax、残余尿量、前列腺体积、移行区体积、tPSA、fPSA及PSAD均可能会增加AUR发生的风险,其中症状严重程度、Qmax、残余尿量及总PSA与AUR具有高度相关性。
目的：分析合并前列腺组织炎症的前列腺增生症的临床特点,探讨炎症与前列腺增生有关LUTS的相关性及其在前列腺增生症病程中可能起的作用。
方法：对2003年7月至2009年10月间的548例良性前列腺增生症患者的资料进行回顾分析,内容包括年龄、病史、国际前列腺症状评分(IPSS)、生活质量评分(QoL)、前列腺体积、前列腺特异性抗原(PSA)、最大尿流率、急性尿潴留和治疗方式。
结果：合并前列腺组织炎症的患者504例(91.97%),该组病史(62.10±45.21月)延长,IPSS/QoL (26.07±7.13/4.7±0.5)评分明显增加、前列腺体积(63.37±40.81cm3)和移行区体积(32.77±25.69cm3)显著增大,最大尿流率(5.75±5.37ml／s)减小,发生急性尿潴留的几率增高,接受外科治疗的比例也较大。但是,年龄和PSA相关值(tPSA、fPSA、f/tPSA、PSAD)无明显差异。
结论：前列腺炎症在前列腺增生组织中非常普遍。炎症存在可能会加重良性前列腺增生症患者的下尿路症状,增加急性尿潴留发生及前列腺增生症相关手术的风险。炎症可能是促进前列腺增生症发生及进展一个重要因素。
目的：比较经尿道前列腺等离子双极电切术(PKRP)和经尿道前列腺汽化电切术(TUVRP)的手术疗效及安全性,为前列腺增生症(BPH)有关LUTS的治疗提供最佳选择。
研究方法：回顾性分析2003年7月至2009年10月在我院行TUVRP和PKRP治疗341例BPH患者的临床资料,比较两者之间的手术时间、术中出血及输血量、术后冲洗及导尿管拔管时间、IPSS、QoL及Qmax。
结果：所有患者手术顺利,未发生明显的术中并发症。TUVRP组(193例)手术时间96.60±52.05min及术后冲洗时间2.62±0.99天,均长于PKRP组(148例)的84.96±28.93min和2.32±1.33天(P<0.05)。在术中出血量、输血量、导尿管拔除时间、住院时间方面,TUVRP组和PKRP组无显著性差异(P>0.05)。出院时,TUVRP组的IPSS、QoL、Qmax分别为8.38±5.86分、1.87±1.46分、17.98±7.33ml/s, PKRP组分别为7.86±5.87分、2.09±2.12分,16.77±9.69ml／s,两组指标均较术前有明显改善,(P<0.05)。IPSS分类症状评分中,TUVRP组和PKRP组的储尿期症状评分和排尿期症状评分分别为4.99±3.10、3.44±3.80,5.00±2.96分、2.26±2.98分,两组指标均较术前有明显改善(P<0.05)。两组间比较,TUVRP组IPSS、储尿期症状评分、排尿期症状评分、QoL评分和Qmax的改善较PKRP组无明显差异(P>0.05)。
结论：TUVRP和PKRP的手术效果与术前比较均有明显差异,都是治疗BPH有关LUTS安全、有效的方法。PKRP组在手术时间、术后冲洗时间等方面均优于TUVRP组,而在术中出血量及输血量、导尿管拔除时间、住院时间、IPSS、QoL、Qmax等方面无显著差异。PKRP似乎较TUVRP的切割效率更高,但在改善LUTS等短期疗效方面,两者并无明显差别。
Objective:To assess the prevalence, age distribution and presentation of low urinary tract symptoms (LUTS) in adult men.
Methods:A random sample was obtained from men coming to our hospital for healthy physical examination during the period of 2008. By completion of the IPSS questionnaire and general health information, 1048 men aged 30-80 years old were assigned into five groups according to 10-year age stratum.The occurrence of symptoms and severity of discomfort from the respondents were assessed.
Results:The occurrence of LUTS for each group was as follow. The average IPSS score was 2.48±0.38,3.80±0.53,4.78±1.07,5.33±0.68, 6.80±1.66 in 347 men in 30-39,311 men in 40-49,114 men in 50-59,207 men in 60-69,69 men in 70-79 years of age group respectively. And the average score of storage urinary symptoms in each group was 1.20,1.66,2.24,2.57,3.20; average score of voiding symptoms was 1.28,2.14,2.54,2.76,3.59; average score of the quality of life (QoL) was 1.78±1.42,1.84±0.30,1.89±1.04,2.03±1.08,2.07±1.92 respectively. The incidence of LUTS in different age groups was correlated with age (x2=70.46, P<0.005). IPSS total score, voiding symptom score and storage symptoms score were positively correlated with QoL score, in which storage symptoms had a more impact on the quality of life than voiding symptoms.
Conclusions:LUTS are relatively widespread in adult healthy males more than 30 years of age. The incidence of LUTS and symptom scores increase with age. The more severe symptoms of LUTS, the greater impact on QoL, in which storage symptoms have a greater impact on QoL than voiding symptoms (The correlation coefficient between the storage symptom score, voiding symptom score and QoL are r=0.966(P<0.05), r=0.931(P<0.05), respectively)
Objective:To explore the clinical characteristics of LUTS suggestive of BPH and their impact on patients'quality of life(QoL).
Methods:548 patients with BPH were enrolled from July 2003 to October 2009 and their clinical data were studied retrospectively. Data on International Prostate Symptom Questionnaire Score (IPSS), a self-designed nocturia symptom score sheet and sexual function questionnaire (MSF-4) filled out by patients when they hospitalized was anlyzed.
Results:548 cases of patients with LUTS, moderate (8-19 points) accounted for 24.8% and severe (20-35 points) accounted for 75.2%. LUTS and its individual symptoms were positively associated with age, but less relevant, which were also positively correlated with QoL. Among the individual urinary symptoms, nocturnal score(Q7) correlated most with QoL, followed by dribbling urine (Q1), inability to urinate (Q5). 28.6%(157/548) of patients considered nocturnal as the greatest impact on their QoL, mainly affecting their sleep (NQ5), followed by fatigue and decreased attention in next day (NQ1),worring about the impact on family or partner's sleep (NQ6). The Spearman rank correlation analysis showed that there was a positive correlation between IPSS and MSF-4 score (P<0.0001), in which nocturia, dysuria, and urinary frequency were the serious urinary symptoms that affected sexual function of patients (r=0.20648,020635,0.18861).
Conclusion:LUTS seriously affect QoL of patients with BPH, including the impact on sexual function.More attention on the further study of BPH patients with nocturia should be paid in order to reduce its disturbance of patients'sleep and life.
Objective:To explore the relationship between different clinical factors and lower urinary tract symptoms (LUTS) suggestive of benign prostate hyperplasia (BPH), in order to understand the impact of the risk factors on BPH related LUTS.
Methods:548 patients with BPH were enrolled from July 2003 to Octorber 2009 and their clinical data were studied retrospectively. The impact of various clinical factors such as age, medical history, maximum urinary flow rate (Qmax), total prostate volume, transition zone volume, transition zone index, total PSA, f/tPSA and prostatic inflammation on IPSS scores were analyzed, and multiple liner regression analysis was also conducted.
Results:Among all the clinical factors mentioned above, age, transition zone volume, Qmax, PSA and prostatic inflammation had a significant impact on the IPSS score. IPSS scores increased significantly with the increase of age and transitional zone volume, while IPSS scores increased significantly with the reduction in Qmax (P<0.05). IPSS scores were significantly higher in the group of PSA≥4ng/ml than that of PSA<4ng/ml (P<0.05), however, there was no difference between the group of PSA range of 4-10ng/ml and that of PSA≥10ng/ml (P<0.05). Patients with prostate inflammation had much higher IPSS score than those patients without prostate inflammation (P<0.05). Further analysis by multiple liner regression found that Qmax and prostate tissue inflammation were closely correlated with the IPSS score among all the possible risk factors (β=-0.807,5.736;P<0.001).
Conclusion:This study shows that prostate tissue inflammation and Qmax have a remarkable impact on the severity of LUTS, and other clinical factors such as patient's age, transition zone volume and PSA value have a limited impact on the severity of LUTS suggestive of BPH as no significance is found after multiple liner regression analysis.
Objective:Acute retention of urine (AUR) is a common urological condition that often needs an emergence management. One of the most common causes of acute urinary retention is benign prostatic hyperplasia (BPH) which is a common disease in aging male population. This study attempts to explore the risk factors of AUR ocurred in BPH patients, thus reasonable preventative measures are taken for the treatment of BPH patients.
Methods:Total 548 patients with BPH were enrolled from Jul 2003 to Oct 2009 and their clinical data were studied retrospectively. Clinical data such as patient's age, medical history, IPSS and QoL score, Qmax, residual urine volume, prostate volume, transition zone volume, transition zone index, tPSA and fPSA, and PSAD was analyzed statistically.
Results:In 548 cases of BPH patients involved in the investigation, development of AUR was found in 164 cases (29.9%), not in 384 cases (70.1%). Patient's age, IPSS score, Qmax, residual urine volume, prostate volume, transition zone volume, tPSA and fPSA including f/tPSA, and PSAD were significantly different in two groups (P<0.05), while there was no significant difference in the disease duration and transition zone index between the two groups. Further Multivariate Logistic regression analysis showed that symptom severity, residual urine volume, tPSA, and Qmax were the most risk factors for predicting the development of AUR.
Conclusions:BPH patient's age, IPSS score, Qmax, residual urine volume, prostate volume, transition zone volume, tPSA and fPSA, and PSAD are likely to increase the risk of AUR, in which symptom severity, Qmax, residual urine volume and total PSA are the most significant predictors for acute retention.
Objective:To analyze the clinical characteristics of benign prostate hyperplasia (BPH) with prostate inflammation,and to investigate the relationship between inflammation and lower urinary tract symptoms (LUTS) suggestive of BPH and the possible role of inflammation in the progression of BPH.
Methods:From July 2003 to Octorber 2009,548 patients diagnosed with BPH were enrolled in this study, and several items including age, history, IPSS, volume of prostate, prostatic-specific antigen (PSA) and related parameter, Qmax, acute urinary retention (AUR) and the way of treatment were analyzed.
Results:504 cases (91.97%) were identified as prostatitis, and those patients'history (62.10±45.21) were longer and their scores of IPSS/QoL (26.07±7.1.3/4.7±0.5) were higher than that of patients without prostatitis. The total volume of prostate and transitional zone were 63.37±40.81cm3 and 32.77±25.69 cm3 respectively in patients with BPH combined with prostatitis, which were larger than those of the patients without prostatitis. Patients with prostatitis felt more uncomfortable about voiding symptoms than the other group.Their maximum flow rate (5.75±5.37ml/s) were decreased and risk of AUR were increased, and the proportion of BPH-related surgery were higher. On the other hand, there were no significant differences about patients'age, tPSA, fPSA, f/tPSA and PSAD between two groups.
Conclusion:Prostatitis in benign prostatic hyperplasia is very common. LUTS may be aggravated by the existence of inflammation in benign prostatic hyperplasia, and the inflammation may increase the risk in occurrence of AUR and BPH-related surgery. Prostate inflammation may be an important factor in occurrence and progression of LUTS suggestive of BPH.
Objective:To compare the surgical efficacy and safety of transurethral Plasma Kinetic Resection of the Prostate (PKRP) and transurethral vaporization resection of the prostate (TUVRP), so as to provide the best choice of the treatment for LUTS suggestive of benign prostatic hyperplasia (BPH).
Methods:The clinical data of 341 patients with BPH treated by PKRP and TUVRP from July 2003 to October 2009 in our hospital was analyzed retrospectively, and the operative time, intraoperative blood loss and blood transfusion, post-operative bladder irrigation and catheter extubation time, IPSS, QoL, and Qmax between the two groups were compared.
Result:The operations were completed successfully in all patients and no significant intraoperative complications occurred. The operation time (96.60±52.05min), post-operative washing time (2.62±0.99 days) of TUVRP group (193 cases) were longer than that (84.96±28.93min) (2.32±1.33 days) of PKRP group (148 cases) (P<0.05). No significant difference was found between two groups in the intraoperative blood loss, blood transfusion, catheter removal time, hospitalization time (P>0.05). IPSS, QoL, Qmax of TUVRP group were 8.38±5.86min,1.87±1.46min, 17.98±7.33ml/s, that of PKRP group were 7.86±5.87 min,2.09±2.12min, 16.77±9.69ml/s,these indicators of both groups improved significantly than that before surgery, (P<0.05). The storage and voiding symptom score of TUVRP group and PKRP group were 4.99±3.10,3.44±3.80 and 5.00±2.96min,2.26±2.98 points, which improved significantly than those before surgery (P<0.05). There was no significant difference existed between this two groups in parameters improvement of IPSS, including storage symptom score and voiding symptom score, QoL and Qmax (P>0.05).
Conclusions:The post-operation results of TUVRP and PKRP improve remarkably compared with preoperation, and both are safe and effective methods for the treatment of LUTS suggestive of benign prostatic hyperplasia. PKRP is better on the operation time and the postoperative irrigating time than TUVRP in this study, however, there is no significant difference between the two groups in intraoperative blood loss and blood transfusion, catheter removal time, hospitalization time, IPSS and QoL score, Qmax. PKRP seems to be faster than TUVRP in cutting efficiency, but this two procedures have similar effects on the short term efficacy such as improving LUTS.
研究方法：采用国际前列腺症状评分问卷(IPSS)表调查前来我院进行健康体检的成年男性1048人,年龄30岁-80岁,以10岁为一年龄段,分为5个年龄段,评估被调查者的LUTS发生情况。
结果：各组LUTS发生的情况为：30岁年龄段347人,平均IPSS评分2.48±0.38；40岁年龄段311人,平均IPSS评分3.80±0.53；50岁年龄段114人,平均IPSS评分4.78±1.07；60岁年龄段207人,平均IPSS评分5.33±0.68；70岁年龄段69人,平均IPSS评分6.80±1.66。其中各年龄组储尿期症状平均评分分别为：1.20,1.66,2.24,2.57,3.20；排尿期症状平均评分分别为：1.28,2.14,2.54,2.76,3.59；生活质量平均评分为：1.78±1.42,1.84±0.30,1.89±1.04,2.03±1.08,2.07±1.92。不同年龄组男性LUTS发生率与年龄相关(χ2=70.46,P<0.005)。IPSS总评分、排尿期症状评分及储尿期症状评分与生活质量评分呈正相关,其中储尿期症状比排尿期症状对生活质量影响更大些(储尿期评分、排尿期评分与QoL评分相关系数分别为：r=0.966(P<0.05),r=0.931(P<0.05))。
结论：LUTS症状在成年健康男性中较普遍存在,发病率随年龄增大而增加。LUTS症状越重,对生活质量影响越大,而储尿期症状较排尿期症状对生活质量影响更大些。
目的：探讨前列腺增生症(BPH)患者出现下尿路症状(LUTS)的临床特点及其对患者生活质量的影响。
方法：对2003年7月至2009年10月收治的548例前列腺增生症患者的资料进行回顾性研究。分析患者住院时填写的国际前列腺症状问卷调查表(IPSS)/自行设计的夜尿症状评分表及性功能问卷调查表(MSF-4)上的数据,并对这些数据进行统计学分析。
结果：548例患者LUTS中,中度(8-19分)占24.8%,重度(20-35分)占75.2%。LUTS及其中各单个症状均与年龄存在正相关但相关性较小。LUTS及其中各单个症状与QoL正相关,症状评分越高,QoL评分也高。其中夜尿增多(NQ7)与QoL相关性最大,其次是排尿不尽(NQ1)、排尿无力(NQ5)。28.6%(157／548)的患者认为夜尿增多对自己影响最大,主要影响患者的睡眠(NQ5),其次是引起患者次日疲倦、注意力下降(NQ1)及担心影响家人或伴侣的睡眠(NQ6)。经Spearman等级相关分析发现IPSS评分与MSF-4评分存在正相关(P<0.0001),其中夜尿增多、排尿困难及尿频是影响患者性功能最大的三个尿路症状(r为0.20648、020635、0.18861)。
结论：LUTS严重地影响BPH患者的生活质量,并影响患者的性功能。应重视对BPH患者夜尿增多的研究及其对患者睡眠及生活质量的影响。
目的：探讨不同的临床因素与前列腺增生症(BPH)相关下尿路症状(LUTS)之间的关系,了解影响BPH有关LUTS的危险因素。
方法：对2003年7月至2009年10月收治的548例前列腺增生症患者的资料进行回顾性研究。分析不同年龄、病史、最大尿流率、前列腺总体积、移行区体积、移行区指数、总PSA、游总比(f/tPSA)、组织炎症对IPSS值的影响,并进行多元线性回归分析。
结果：年龄、移行带体积、Qmax、PSA及前列腺组织炎症对IPSS评分影响显著。随着年龄增大和移行带体积的增加,IPSS值变大；随着最大尿流率的减少,IPSS值显著增加(P<0.05)。当PSA≥4ng/ml时,IPSS值要显著大于<4ng/ml组的IPSS值(P<0.05),但是介于4-10ng/ml组和≥10ng/ml组的IPSS评分并无差异(P<0.05)。合并前列腺组织炎症患者的IPSS值要显著高于非炎症组(P<0.05)。进一步通过多元线性回归分析,发现所有可能影响IPSS评分的因素中,Qmax和前列腺组织炎症与IPSS评分密切相关(p=-0.807,5.736；P<0.001)。
结论：前列腺组织炎症和Qmax对下尿路症状的影响最显著。其他的临床因素如患者年龄、移行带体积和PSA值对BPH患者的下尿路症状影响有限,经过多因素回归分析发现并无显著性。
目的：急性尿储留(AUR)是一种常见的泌尿外科需要急诊处理的情况。前列腺增生症(BPH)是老年男性的一种常见疾病,是引起AUR最常见的原因之一。本研究试图探讨BPH患者发生AUR的危险因素,以便在治疗BPH患者时采取合理的预防措施。
方法：对2003年7月至2009年12月收治的548例前列腺增生症患者的资料进行回顾性研究。对患者的年龄、病程、IPSS评分、Qmax、残余尿量、前列腺体积、移行区体积、移行区指数、tPSA、fPSA、游总比及PSAD等数据进行统计学分析。
结果：548例参与调查的BPH患者中,合并AUR的患者为164例(29.9%),不伴有AUR的患者为384例(70.1%)。两组患者的年龄、IPSS评分、Qmax、残余尿量、前列腺体积、移行区体积、tPSA、fPSA、游总比及PSAD有显著差异(P<0.05),而两组间的病程和移行区指数无显著性差异。进一步多因素Logistic回归分析显示,IPSS、残余尿量、tPSA及Qmax是AUR发生最相关的因素。
结论：BPH患者的年龄、IPSS评分、Qmax、残余尿量、前列腺体积、移行区体积、tPSA、fPSA及PSAD均可能会增加AUR发生的风险,其中症状严重程度、Qmax、残余尿量及总PSA与AUR具有高度相关性。
目的：分析合并前列腺组织炎症的前列腺增生症的临床特点,探讨炎症与前列腺增生有关LUTS的相关性及其在前列腺增生症病程中可能起的作用。
方法：对2003年7月至2009年10月间的548例良性前列腺增生症患者的资料进行回顾分析,内容包括年龄、病史、国际前列腺症状评分(IPSS)、生活质量评分(QoL)、前列腺体积、前列腺特异性抗原(PSA)、最大尿流率、急性尿潴留和治疗方式。
结果：合并前列腺组织炎症的患者504例(91.97%),该组病史(62.10±45.21月)延长,IPSS/QoL (26.07±7.13/4.7±0.5)评分明显增加、前列腺体积(63.37±40.81cm3)和移行区体积(32.77±25.69cm3)显著增大,最大尿流率(5.75±5.37ml／s)减小,发生急性尿潴留的几率增高,接受外科治疗的比例也较大。但是,年龄和PSA相关值(tPSA、fPSA、f/tPSA、PSAD)无明显差异。
结论：前列腺炎症在前列腺增生组织中非常普遍。炎症存在可能会加重良性前列腺增生症患者的下尿路症状,增加急性尿潴留发生及前列腺增生症相关手术的风险。炎症可能是促进前列腺增生症发生及进展一个重要因素。
目的：比较经尿道前列腺等离子双极电切术(PKRP)和经尿道前列腺汽化电切术(TUVRP)的手术疗效及安全性,为前列腺增生症(BPH)有关LUTS的治疗提供最佳选择。
研究方法：回顾性分析2003年7月至2009年10月在我院行TUVRP和PKRP治疗341例BPH患者的临床资料,比较两者之间的手术时间、术中出血及输血量、术后冲洗及导尿管拔管时间、IPSS、QoL及Qmax。
结果：所有患者手术顺利,未发生明显的术中并发症。TUVRP组(193例)手术时间96.60±52.05min及术后冲洗时间2.62±0.99天,均长于PKRP组(148例)的84.96±28.93min和2.32±1.33天(P<0.05)。在术中出血量、输血量、导尿管拔除时间、住院时间方面,TUVRP组和PKRP组无显著性差异(P>0.05)。出院时,TUVRP组的IPSS、QoL、Qmax分别为8.38±5.86分、1.87±1.46分、17.98±7.33ml/s, PKRP组分别为7.86±5.87分、2.09±2.12分,16.77±9.69ml／s,两组指标均较术前有明显改善,(P<0.05)。IPSS分类症状评分中,TUVRP组和PKRP组的储尿期症状评分和排尿期症状评分分别为4.99±3.10、3.44±3.80,5.00±2.96分、2.26±2.98分,两组指标均较术前有明显改善(P<0.05)。两组间比较,TUVRP组IPSS、储尿期症状评分、排尿期症状评分、QoL评分和Qmax的改善较PKRP组无明显差异(P>0.05)。
结论：TUVRP和PKRP的手术效果与术前比较均有明显差异,都是治疗BPH有关LUTS安全、有效的方法。PKRP组在手术时间、术后冲洗时间等方面均优于TUVRP组,而在术中出血量及输血量、导尿管拔除时间、住院时间、IPSS、QoL、Qmax等方面无显著差异。PKRP似乎较TUVRP的切割效率更高,但在改善LUTS等短期疗效方面,两者并无明显差别。
Objective:To assess the prevalence, age distribution and presentation of low urinary tract symptoms (LUTS) in adult men.
Methods:A random sample was obtained from men coming to our hospital for healthy physical examination during the period of 2008. By completion of the IPSS questionnaire and general health information, 1048 men aged 30-80 years old were assigned into five groups according to 10-year age stratum.The occurrence of symptoms and severity of discomfort from the respondents were assessed.
Results:The occurrence of LUTS for each group was as follow. The average IPSS score was 2.48±0.38,3.80±0.53,4.78±1.07,5.33±0.68, 6.80±1.66 in 347 men in 30-39,311 men in 40-49,114 men in 50-59,207 men in 60-69,69 men in 70-79 years of age group respectively. And the average score of storage urinary symptoms in each group was 1.20,1.66,2.24,2.57,3.20; average score of voiding symptoms was 1.28,2.14,2.54,2.76,3.59; average score of the quality of life (QoL) was 1.78±1.42,1.84±0.30,1.89±1.04,2.03±1.08,2.07±1.92 respectively. The incidence of LUTS in different age groups was correlated with age (x2=70.46, P<0.005). IPSS total score, voiding symptom score and storage symptoms score were positively correlated with QoL score, in which storage symptoms had a more impact on the quality of life than voiding symptoms.
Conclusions:LUTS are relatively widespread in adult healthy males more than 30 years of age. The incidence of LUTS and symptom scores increase with age. The more severe symptoms of LUTS, the greater impact on QoL, in which storage symptoms have a greater impact on QoL than voiding symptoms (The correlation coefficient between the storage symptom score, voiding symptom score and QoL are r=0.966(P<0.05), r=0.931(P<0.05), respectively)
Objective:To explore the clinical characteristics of LUTS suggestive of BPH and their impact on patients'quality of life(QoL).
Methods:548 patients with BPH were enrolled from July 2003 to October 2009 and their clinical data were studied retrospectively. Data on International Prostate Symptom Questionnaire Score (IPSS), a self-designed nocturia symptom score sheet and sexual function questionnaire (MSF-4) filled out by patients when they hospitalized was anlyzed.
Results:548 cases of patients with LUTS, moderate (8-19 points) accounted for 24.8% and severe (20-35 points) accounted for 75.2%. LUTS and its individual symptoms were positively associated with age, but less relevant, which were also positively correlated with QoL. Among the individual urinary symptoms, nocturnal score(Q7) correlated most with QoL, followed by dribbling urine (Q1), inability to urinate (Q5). 28.6%(157/548) of patients considered nocturnal as the greatest impact on their QoL, mainly affecting their sleep (NQ5), followed by fatigue and decreased attention in next day (NQ1),worring about the impact on family or partner's sleep (NQ6). The Spearman rank correlation analysis showed that there was a positive correlation between IPSS and MSF-4 score (P<0.0001), in which nocturia, dysuria, and urinary frequency were the serious urinary symptoms that affected sexual function of patients (r=0.20648,020635,0.18861).
Conclusion:LUTS seriously affect QoL of patients with BPH, including the impact on sexual function.More attention on the further study of BPH patients with nocturia should be paid in order to reduce its disturbance of patients'sleep and life.
Objective:To explore the relationship between different clinical factors and lower urinary tract symptoms (LUTS) suggestive of benign prostate hyperplasia (BPH), in order to understand the impact of the risk factors on BPH related LUTS.
Methods:548 patients with BPH were enrolled from July 2003 to Octorber 2009 and their clinical data were studied retrospectively. The impact of various clinical factors such as age, medical history, maximum urinary flow rate (Qmax), total prostate volume, transition zone volume, transition zone index, total PSA, f/tPSA and prostatic inflammation on IPSS scores were analyzed, and multiple liner regression analysis was also conducted.
Results:Among all the clinical factors mentioned above, age, transition zone volume, Qmax, PSA and prostatic inflammation had a significant impact on the IPSS score. IPSS scores increased significantly with the increase of age and transitional zone volume, while IPSS scores increased significantly with the reduction in Qmax (P<0.05). IPSS scores were significantly higher in the group of PSA≥4ng/ml than that of PSA<4ng/ml (P<0.05), however, there was no difference between the group of PSA range of 4-10ng/ml and that of PSA≥10ng/ml (P<0.05). Patients with prostate inflammation had much higher IPSS score than those patients without prostate inflammation (P<0.05). Further analysis by multiple liner regression found that Qmax and prostate tissue inflammation were closely correlated with the IPSS score among all the possible risk factors (β=-0.807,5.736;P<0.001).
Conclusion:This study shows that prostate tissue inflammation and Qmax have a remarkable impact on the severity of LUTS, and other clinical factors such as patient's age, transition zone volume and PSA value have a limited impact on the severity of LUTS suggestive of BPH as no significance is found after multiple liner regression analysis.
Objective:Acute retention of urine (AUR) is a common urological condition that often needs an emergence management. One of the most common causes of acute urinary retention is benign prostatic hyperplasia (BPH) which is a common disease in aging male population. This study attempts to explore the risk factors of AUR ocurred in BPH patients, thus reasonable preventative measures are taken for the treatment of BPH patients.
Methods:Total 548 patients with BPH were enrolled from Jul 2003 to Oct 2009 and their clinical data were studied retrospectively. Clinical data such as patient's age, medical history, IPSS and QoL score, Qmax, residual urine volume, prostate volume, transition zone volume, transition zone index, tPSA and fPSA, and PSAD was analyzed statistically.
Results:In 548 cases of BPH patients involved in the investigation, development of AUR was found in 164 cases (29.9%), not in 384 cases (70.1%). Patient's age, IPSS score, Qmax, residual urine volume, prostate volume, transition zone volume, tPSA and fPSA including f/tPSA, and PSAD were significantly different in two groups (P<0.05), while there was no significant difference in the disease duration and transition zone index between the two groups. Further Multivariate Logistic regression analysis showed that symptom severity, residual urine volume, tPSA, and Qmax were the most risk factors for predicting the development of AUR.
Conclusions:BPH patient's age, IPSS score, Qmax, residual urine volume, prostate volume, transition zone volume, tPSA and fPSA, and PSAD are likely to increase the risk of AUR, in which symptom severity, Qmax, residual urine volume and total PSA are the most significant predictors for acute retention.
Objective:To analyze the clinical characteristics of benign prostate hyperplasia (BPH) with prostate inflammation,and to investigate the relationship between inflammation and lower urinary tract symptoms (LUTS) suggestive of BPH and the possible role of inflammation in the progression of BPH.
Methods:From July 2003 to Octorber 2009,548 patients diagnosed with BPH were enrolled in this study, and several items including age, history, IPSS, volume of prostate, prostatic-specific antigen (PSA) and related parameter, Qmax, acute urinary retention (AUR) and the way of treatment were analyzed.
Results:504 cases (91.97%) were identified as prostatitis, and those patients'history (62.10±45.21) were longer and their scores of IPSS/QoL (26.07±7.1.3/4.7±0.5) were higher than that of patients without prostatitis. The total volume of prostate and transitional zone were 63.37±40.81cm3 and 32.77±25.69 cm3 respectively in patients with BPH combined with prostatitis, which were larger than those of the patients without prostatitis. Patients with prostatitis felt more uncomfortable about voiding symptoms than the other group.Their maximum flow rate (5.75±5.37ml/s) were decreased and risk of AUR were increased, and the proportion of BPH-related surgery were higher. On the other hand, there were no significant differences about patients'age, tPSA, fPSA, f/tPSA and PSAD between two groups.
Conclusion:Prostatitis in benign prostatic hyperplasia is very common. LUTS may be aggravated by the existence of inflammation in benign prostatic hyperplasia, and the inflammation may increase the risk in occurrence of AUR and BPH-related surgery. Prostate inflammation may be an important factor in occurrence and progression of LUTS suggestive of BPH.
Objective:To compare the surgical efficacy and safety of transurethral Plasma Kinetic Resection of the Prostate (PKRP) and transurethral vaporization resection of the prostate (TUVRP), so as to provide the best choice of the treatment for LUTS suggestive of benign prostatic hyperplasia (BPH).
Methods:The clinical data of 341 patients with BPH treated by PKRP and TUVRP from July 2003 to October 2009 in our hospital was analyzed retrospectively, and the operative time, intraoperative blood loss and blood transfusion, post-operative bladder irrigation and catheter extubation time, IPSS, QoL, and Qmax between the two groups were compared.
Result:The operations were completed successfully in all patients and no significant intraoperative complications occurred. The operation time (96.60±52.05min), post-operative washing time (2.62±0.99 days) of TUVRP group (193 cases) were longer than that (84.96±28.93min) (2.32±1.33 days) of PKRP group (148 cases) (P<0.05). No significant difference was found between two groups in the intraoperative blood loss, blood transfusion, catheter removal time, hospitalization time (P>0.05). IPSS, QoL, Qmax of TUVRP group were 8.38±5.86min,1.87±1.46min, 17.98±7.33ml/s, that of PKRP group were 7.86±5.87 min,2.09±2.12min, 16.77±9.69ml/s,these indicators of both groups improved significantly than that before surgery, (P<0.05). The storage and voiding symptom score of TUVRP group and PKRP group were 4.99±3.10,3.44±3.80 and 5.00±2.96min,2.26±2.98 points, which improved significantly than those before surgery (P<0.05). There was no significant difference existed between this two groups in parameters improvement of IPSS, including storage symptom score and voiding symptom score, QoL and Qmax (P>0.05).
Conclusions:The post-operation results of TUVRP and PKRP improve remarkably compared with preoperation, and both are safe and effective methods for the treatment of LUTS suggestive of benign prostatic hyperplasia. PKRP is better on the operation time and the postoperative irrigating time than TUVRP in this study, however, there is no significant difference between the two groups in intraoperative blood loss and blood transfusion, catheter removal time, hospitalization time, IPSS and QoL score, Qmax. PKRP seems to be faster than TUVRP in cutting efficiency, but this two procedures have similar effects on the short term efficacy such as improving LUTS.
引文
[1]Chapple C R. Lower Urinary Tract Symptoms Revisited[J]. European Urology, 2009,56(1):21-23.
[2]Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function:report from the standardisation sub-committee of the International Continence Society.[J]. Urology,2003,61(1):37-49.
[3]Kakizaki H, Matsuura S, Mitsui T, Ameda K, Tanaka H K T. Questionnaire analysis on sex difference in lower urinary tract symptoms.[J]. Urology,2002,59(1): 58-62.
[4]Schatzl G, Temml C, Waldmuller J, Thurridl T, Haidinger G M S. A comparative cross-sectional study of lower urinary tract symptoms in both sexes.[J]. Eur Urol, 2001,40(2):213-219.
[5]Coyne K S, Sexton C C, Thompson C L, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden:results from the Epidemiology of LUTS (EpiLUTS) study.[J]. BJU Int,2009.
[6]Abrams P. LUTS, BPH, BPE, BPO:A Plea for the Logical Use of Correct Terms. [J].Rev Urol,1999,1(1):65.
[7]Andersson K E. Storage and voiding symptoms:pathophysiologic aspects.[J]. Urology,2003,62(5 Suppl 2):3-10.
[8]Spigt M G, Van S C, Van K P, et al. Pathophysiological aspects of bladder dysfunction:a new hypothesis for the prevention of 'prostatic' symptoms.[J]. Med Hypotheses,2004,62(3):448-452.
[9]那彦群.中国泌尿外科疾病诊断治疗指南(2007版)[J].：167-204.
[10]Chute C G, Panser L A, Girman C J, et al. The prevalence of prostatism:a population-based survey of urinary symptoms.[J]. J Urol,1993,150(1):85-89.
[11]Trueman P, Hood Sc, Nayak Us M M. Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK.[J]. BJU Int,1999, 83(4):410-415.
[12]Verhamme K M, Dieleman J P, Bleumink G S, et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care-the Triumph project.[J]. Eur Urol,2002,42(4):323-328.
[13]Horchani A, Binous M Y, Ben H A, et al. [Prevalence of benign prostatic hyperplasia in general practice and practical approach of the Tunisian general practitioner (Prevapt study)][J]. Tunis Med,2007,85(8):619-624.
[14]Berges R. [Epidemiology of benign prostatic syndrome:Associated risks and management data in German men over age 50.][J]. Urologe A,2008,47(2):141-148.
[15]Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia.[J]. Rev Urol,2004,6 Suppl 9:3-10.
[16]Homma Y, Kawabe K, Tsukamoto T, et al. Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the international prostate symptom score[J]. Int J Urol,1997,4(1):40-46.
[17]Mcvary K. Lower urinary tract symptoms and sexual dysfunction:epidemiology and pathophysiology.[J]. BJU Int,2006,97 Suppl 2:23-8445.
[18]蒋先镇；邓素容；何乐业.I-PSS和UFR对女性排尿行为的临床分析。[J].中华泌尿外科杂志,1998,19(4)：233-235.
[19]Irwin D E, Milsom I, Kopp Z, et al. Prevalence, Severity, and Symptom Bother of Lower Urinary Tract Symptoms among Men in the EPIC Study:Impact of Overactive Bladder.[J]. Eur Urol,2009.
[20]Gades N M, Jacobson D J, Girman C J, et al. Prevalence of conditions potentially associated with lower urinary tract symptoms in men.[J]. BJU Int,2005,95(4):549-553.
[1]Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function:report from the Standardisation Sub-committee of the International Continence Society.[J]. Neurourol Urodyn,2002,21(2):167-178.
[2]Berry S J, Coffey D S, Walsh P C, et al. The development of human benign prostatic hyperplasia with age.[J]. J Urol.1984,132(3):474-479.
[3]Chute C G, Panser L A, Girman C J, et al. The prevalence of prostatism:a population-based survey of urinary symptoms.[J]. J Urol,1993,150(1):85-89.
[4]Welch G, Weinger K, Barry M J. Quality-of-life impact of lower urinary tract symptom severity:results from the Health Professionals Follow-up Study.[J]. Urology, 2002,59(2):245-250.
[5]Saigal C S, Joyce G. Economic costs of benign prostatic hyperplasia in the private sector.[J]. J Urol,2005,173(4):1309-1313.
[6]Marquis P, Marrel A. Reproducibility and clinical and concurrent validity of the MSF-4:a four-item male sexual function questionnaire for patients with benign prostatic hyperplasia.[J]. Value Health,2001,4(4):335-343.
[7]Kaplan S A. Reproducibility and clinical and concurrent validity of the MSF-4:a four-item male sexual function questionnaire for patients with benign prostatic hyperplasia.[J]. J Urol.2002,168(4 Pt 1):1661-1662.
[8]Andersson S O, Rashidkhani B, Karlberg L, et al. Prevalence of lower urinary tract symptoms in men aged 45-79 years:a population-based study of 40 000 Swedish men.[J]. BJU Int,2004,94(3):327-331.
[9]Irwin D E, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries:results of the EPIC study.[J]. Eur Urol,2006,50(6):1306-1314,1314-1315.
[10]Coyne K S, Sexton C C, Thompson C L, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden:results from the Epidemiology of LUTS (EpiLUTS) study.[J]. BJU Int,2009.
[11]Vandoninck V, Bemelmans B L, Mazzetta C, et al. The prevalence of urinary incontinence in community-dwelling married women:a matter of definition.[J]. BJU Int,2004,94(9):1291-1295.
[12]Terai A, Matsui Y, Ichioka K, et al. Comparative analysis of lower urinary tract symptoms and bother in both sexes[J]. Urology,2004,63(3):487-491.
[13]Boyle P, Robertson C, Mazzetta C, et al. The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study.[J]. BJU Int,2003,92(4):409-414.
[14]Schatzl G T C W J. A comparative cross-sectional study of lower urinary tract symptoms in both sexes.[J]. Eur Urol,2001,40(2):213-219.
[15]Speakman M J. Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):More Than Treating Symptoms?[J]. European Urology Supplements.The Future of LUTS/BPH:Management beyond the Prostate,2008, 7(11):680-689.
[16]Seim A, Hoyo C, Ostbye T, et al. The prevalence and correlates of urinary tract symptoms in Norwegian men:the HUNT study.[J]. BJU Int,2005,96(1):88-92.
[17]Perrin P, Marionneau N, Cucherat M, et al. Relationship between lower urinary tract symptoms frequency assessed by the IPSS and bothersomeness (SPI) among men older than 50 years old.[J]. Eur Urol,2005,48(4):601-607.
[18]Barry M J, Fowler F J, O'Leary M P, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.[J]. J Urol,1992,148(5):1549-1557,1564.
[19]Peters T J, Donovan J L, Kay H E, et al. The International Continence Society "Benign Prostatic Hyperplasia" Study:the botherosomeness of urinary symptoms.[J]. J Urol,1997,157(3):885-889.
[20]Barry M J, Fowler F J, O'Leary M P, et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association.[J]. Med Care,1995,33(4 Suppl):S145-S155.
[21]Donovan J L, Abrams P, Peters T J, et al. The ICS-'BPH' Study:the psychometric validity and reliability of the ICSmale questionnaire.[J]. Br J Urol,1996,77(4):554-562.
[22]Irwin D E, Milsom I, Kopp Z, et al. Prevalence, Severity, and Symptom Bother of Lower Urinary Tract Symptoms among Men in the EPIC Study:Impact of Overactive Bladder.[J]. Eur Urol,2009.
[23]Robertson C, Link C L, Onel E, et al. The impact of lower urinary tract symptoms and comorbidities on quality of life:the BACH and UREPIK studies.[J]. BJU Int,2007,99(2):347-354.
[24]Logie J, Clifford G M, Farmer R D. Incidence, prevalence and management of lower urinary tract symptoms in men in the UK.[J]. BJU Int,2005,95(4):557-562.
[25]Garraway W M, Collins G N, Lee R J. High prevalence of benign prostatic hypertrophy in the community.[J]. Lancet,1991,338(8765):469-471.
[26]Verhamme K M, Dieleman J P, Bleumink G S, et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project.[J]. Eur Urol,2002,42(4):323-328.
[27]Clifford G M, Logie J, Fanner R D. How do symptoms indicative of BPH progress in real life practice? The UK experience.[J]. Eur Urol,2000,38 Suppl 1:48-53.
[28]Eckhardt M D, Van V G,Van M H, et al. Prevalence and bothersomeness of lower urinary tract symptoms in benign prostatic hyperplasia and their impact on well-being.[J]. J Urol,2001,166(2):563-568.
[29]Roehrborn C G, Mcconnell J D, Saltzman B, et al. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes.[J]. Eur Urol,2002,42(1):1-6.
[30]Haltbakk J, Hanestad B R, Hunskaar S. Diversity of urinary symptoms in patients tentatively diagnosed with benign prostatic hyperplasia referred to a urologic clinic in Norway.[J]. Scand J Urol Nephrol,2004,38(6):454-461.
[31]Abrams P. Nocturia:the major problem in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (LUTS/BPO)[J]. European Urology Supplements,2005,3(6):8-16.
[32]Chartier-Kastler E, Tubaro A. The Measurement of Nocturia and Its Impact on Quality of Sleep and Quality of Life in LUTS/BPH[J]. European Urology Supplements,2006,5(1):3-11.
[33]Schulman C C, Asplund R, Desgrandchamps F, et al. The Impact of Nocturia on Health Status and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)[J]. European Urology Supplements,2005,4(2):1-8.
[34]Scarpa R M. Lower urinary tract symptoms (LUTS):what are the implications for the patients?[J]. Eur Urol,2001,40((suppl 4)):10-20.
[35]Barry M J. Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia.[J]. Urology,2001,58 (6 Suppl 1):25-32,32.
[36]Li M K, Garcia L, Patron N, et al. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.[J]. BJU Int,2008,101(2):197-202.
[37]Jung J H, Jae S U, Kam S C, et al. Correlation between Lower Urinary Tract Symptoms (LUTS) and Sexual Function in Benign Prostatic Hyperplasia:Impact of Treatment of LUTS on Sexual Function.[J]. J Sex Med,2009.
[1]Azadzoi KM, Tarcan T, Siroky MB, et al. Atherosclerosis-induced chronic ischemia causes bladder fibrosis and noncompliance in the rabbit. J Urol,1999,161 (5):1626.
[2]Guess HA, Arrighi HM, Metter EJ, et al. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate 1990,17: 241-246.
[3]万少平,胡礼泉,刘源.武汉市2811例男性下尿路症状问卷调查.中华泌尿外科杂志,2004,25：585-587.
[4]AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapterl:Diagnosis and treatment recommendations. J Urol,2003,170:530-547.
[5]Rosette JD. Madersbacher S, Alivizatos G, et al. EAU Guidelines on benign prostatic hyperplasia (2004). Chapter3:Assessment,2004,13-31.
[6]杨勇,顾方六.第五届国际良性前列腺增生咨询委员会国际科学委员会推荐意见：老年男性下尿路症状的评估和治疗.中华泌尿外科杂志,2001,22：564.
[7]Roehrborn CG. Accurate determination of prostate size via digital rectal examination and transpectal ultra-sound. Urology,1998,51:19-22.
[8]Resnick M, Ackerman R, Bosch J, et al. Fifth International Consultation on BPH. In:Chatelain C, Denis L, Foo S, et al. Benign Prostatic Hyperplasia. Plymbridge Distributions,2000.169-188.
[9]阙艳红,王学梅.双平面经直肠超声诊断良性前列腺增生的探讨.中华男科学,2005,11(03)：191-191.
[10]Thomas AW, Abrams P. Lower urinary tract symptoms. Benign prostatic obstruction and the overactive bladder. BJU Int,2000,85(Suppl 3):57-68.]
[11]双卫兵,王东文,张旭,等.良性前列腺增生膀胱出口梗阻评判指标分析.中华男科学杂志,2004,10(10)：743.
[12]赵永久,任福金,詹朝辉,等.良性前列腺增生与下尿路症状及急性尿潴留的关系.现代泌尿外科杂志,2004,9(3)：172.
[13]高建平.前列腺疾病与下尿路症状.医学研究生学报,2006,19(2)：97-99.
[14]McConnell JD. Benign prostatic hyperplasia:treatment guidelines and patient classification. Br J Urol,1995,76(Suppl 1):29.
[15]Abrams P, Donovan JL, Rosette JJ, et al. International Continence Society "Benign Prostatic Hyperplasia" Study:background, aims and methodology. Neurourol Urodyn,1997,16(2):79-91.
[16]Rosette JJ, Witjes WP, Schafer W, et al. Relationships between lower urinary tract symptoms and bladder outlet obstruction:results from the ICS-"BPH" study. Neurourol Urodyn,1998,17(2):99-108.
[17]McNeal JE. The zonal anatomy of the prostate. Prostate,1981,2(1):35-49.
[18]Homma Y, Gotch M, Takei M, et al. Predictability of conventional tests for the assessment of bladder outlet obstruction in benign prostatic hyperplasia. Int J Urol, 1998,5(1):61-66.
[19]刘跃新,焦志友,陈山,等.经直肠三维超声在前列腺增生症诊断中的应用.中华泌尿外科杂志,1997,18：490-492.
[20]Steven AK, Alexis ET, Lee BP, et al. Transition zone index as a method of assessing benign prostatic hyperplasia:correlation with symptoms, urine flow and detrusor pressure. J Urol,1995,154(5):1764-1769.
[21]Kurita Y, Masuda H, Terada H, et al. Transition zone index as a risk factor for acute urinary retention in benign prostatic hyperplasia. Urology,1998,51(4): 595-600.
[22]华立新,吴宏飞,眭元庚,等.移行区指数预测良性前列腺增生的临床意义.中华泌尿外科杂志,2003,24(1)：59.
[23]应俊,姚德鸿,任晓敏,等.BPH病人血清fPSA/tPSA比值的临床应用.中华男科学,2001,7(3)：167-169.
[24]Vesely S, Knutson T, Damber JE, et al. Relationship between age, prostate volume, prostate-specific antigen, symptom score and uroflowmetry in men with lower urinary tract symptoms. Scand J Urol Nephrol,2003,37:322-328.
[25]Punglia RS, D'Amico AV, Catalona WJ, et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med,2003,349:335-342.
[26]Roehrborn CG, McConnell JD, Sahzman B, et al. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol,2002,42:1-6.
[27]Laniado ME, Ockrim JL, Marronaro A, et al. Serum prostate specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms. BJU Int,2004,94(9):1283-1286.
[28]Babain RJ, Miyashita H, Evans RB, et al. The distribution of prostate specific antigen in men without clinical or pathological evidence of prostate cancer: relationship to gland volume and age. J Urol,1992,147(3):837-840.
[29]Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA,1993,270(7):860-864.
[30]Haese A, Graefen M, Steuber T, et al. Total and Gleason grade 415 cancer volumes are major contributors of human hallihrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign rostat ic biop sies. J Urol,2003,170(6):2269.
[31]McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperp lasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med,1998,338(9):557-563.
[32]华立新,吴宏飞,眭元庚,等.急性尿潴留对血清前列腺特异性抗原的影响.中华男科学,2002,8(2)：134-135.
[33]Oesterling JE, Rice DC, Glenski WJ, et al. Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate specific antigen concent ration. Urology,1993,42(3):276-282.
[34]顾润国.前列腺炎对血清PSA水平的影响.中华男科学杂志,2001,7(2)：55-57.
[35]高中伟,王明珠,贺大林.血清PSA的影响因素.现代泌尿外科杂志,2001,6(2)：60-62.
[36]Yuan JJ, Coplen DE, Petros JA, et al. Effect s of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J Urol,1992,147:810-814.
[37]Dew T, Coker C, Saadeh F, et al. Influence of investigative and operative procedures on serum prostate specific antigen concentration. Ann Clin Biochem,1999, 36:340-346.
[38]施国伟,何家扬,徐火根.直肠指检对PSA、FPSA影响的研究.临床泌尿外科杂志,2002,17(4)：166-168.
[39]Batislam E, Arik AI, Karakoc A, et al. Effect of transurethral indwelling catheter on serum prostate specific antigen level in benign prostatic hyperplasia. Urology, 1997,49(1):50-54.
[40]Tchergen MB, Song JJ, Strawelerman M, et al. Ejaculation increases the serum prostate specific antigen concentration. Urology,1996,47:511-516.
[41]Douglas TH, Morgan TO, McLeod DG, et al. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients. Cancer,1997,80(1):107-114.
[42]Roehrborm CG, Oesterling JE, Olson PJ, et al. Serial prostate specific antigen measurements in men with clinically BPH during a 12 month placebo-controlled study with terazosin. Urology,1997,50:556.
[43]Stenman UH, Aofthan H. Effect of long term treatment with finasteride on free and total PSA in serum. J Urol,1996,155:698A.
[44]Paus E, Nilsson O, Ole P, et al. Stability of free and total prostate specific antigen in serum from parients with prostate carcinoma and benign hyperplasia. J Urol,1998, 159:1599-1650.
[45]Patel D, White PAE, Milford ward A. A comparison of six commercially assays for total and free prostate specific antigen:the predictive value of the ration of free to total PSA. Br J Urol,2000,85:686-689.
[46]杨勇,吴士良,段继宏,等.良性前列腺增生患者逼尿肌功能的评估和治疗对策.中华外科杂志,2001,39(4)：299.
[47]Elbadawi A, Yalla SV, Rdsnick NM. Structural basis of geriatric voiding dysfunction. Ⅱ. Aging detrusor:normal versus impaired contractility. J Urol,1993, 150:1656-1657.
[48]Nakai H, Yamanishi T, Yasuda K, et al. Correlation between lower urinary tract symptoms and urethral function in benign prostatic hyperplasia. Neurourol Urodyn, 2004,23(7):618.
[49]Hampel C, Dolber PC, Smith MP, et al. Modulation of bladder alphal-adrenergic receptor subtype expression by bladder outlet obstruction. J Urol,2002,167(3):1513.
[50]廖利民.尿流率测定.见：金锡御,宋波,主编.临床尿动力学.北京：人民卫生出版社,2002：88-111.
[51]Smith JC. Some theoretical aspects of urethralresistance. Invest Urol,1964,1: 477-481.
[52]Yoshimura N, Yoshida O, Sasa M, et al. Dopamine D-1 receptor-mediated inhibition of micturition reflex by central dopamine from the substantia nigra. Neurourol Urodyn,1992,11(5):535-545.
[53]Menendez V, Cofan F, Talbot R, et al.Urodynamic cvaluation in simultaneous insulin-dependent diabetes mellitus and end stage renal disease. Clin Urol Urology, 1996,155:2001-2004.
[54]Abrams P, Artibani W, Cardozo L, et al. Reviewing the ICS 2002 terminology report:The ongoing debate. Neurourol Urodyn,2006,25(3):293.
[55]Rowe E, Smith C, Laverick L, et al. A prospective, randomized, placebo controlled, double-blind study of pelvic electromagnetic therapy for the treatment of chronic pelvic pain syndrome with 1 year of followup. J Urol,2005,173(6): 2044-2047.
[56]Shahed AR, Shoskes DA. Correlation of beta-endorphin and prostaglandin E2 levels in prostatic fluid of patients with chronic prostatitis with diagnosis and treatment response. J Urol,2001,166(5):1738-1741.
[57]邓春华,梁宏,梅骅,等.前列腺内尿液返流在慢性前列腺炎发病中的作用.中华泌尿外科杂志,1998,19(6)：288-289.
[58]Persson BE, Ronquist G. Evidence for a mechanistic association between nonbacterial prostatitis and levels of urate and creatinine in expressed prostatic secretion. J Urol,1996,155:958-960.
[1]Trachtenberg J. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression.[J]. BJU Int,2005,95 Suppl 4:6-11.
[2]Emberton M, Anson K. Acute urinary retention in men:an age old problem.[J]. BMJ,1999,318(7188):921-925.
[3]Thomas K, Oades G, Taylor-Hay C, et al. Acute urinary retention:what is the impact on patients' quality of life?[J]. BJU Int,2005,95(1):72-76.
[4]那彦群.中国泌尿外科疾病诊断治疗指南[M].1.北京：人民卫生出版社,2007.167-204.
[5]AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations.[J]. J Urol,2003,170(2 Pt 1):530-547.
[6]Emberton M, Elhilali M, Matzkin H,et al. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily. [J]. Urology,2005,66(2):316-322.
[7]Mcconnell J D, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.[J]. N Engl J Med,1998,338(9):557-563.
[8]Jacobsen S J, Jacobson D J, Girman C J, et al. Natural history of prostatism:risk factors for acute urinary retention.[J]. J Urol,1997,158(2):481-487.
[9]Kumar V, Marr C, Bhuvangiri A, et al. A prospective study of conservatively managed acute urinary retention:prostate size matters.[J]. BJU Int,2000,86(7): 816-819.
[10]Klarskov P, Andersen J T, Asmussen C F, et al. Symptoms and signs predictive of the voiding pattern after acute urinary retention in men.[J]. Scand J Urol Nephrol,1987,21(1):23-28.
[11]Thomas K, Chow K, Kirby R S. Acute urinary retention:a review of the aetiology and management.[J]. Prostate Cancer Prostatic Dis,2004,7(1):32-37.
[12]Kefi A, Koseoglu H, Celebi I, et al. Relation between acute urinary retention, chronic prostatic inflammation and accompanying elevated prostate-specific antigen.[J]. Scand J Urol Nephrol,2006,40(2):155-160.
[13]Roehrborn C G. BPH progression:concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.[J]. BJU Int,2008,101 Suppl 3:17-21.
[14]Spiro L H, Labay G, Orkin L A. Prostatic infarction. Role in acute urinary retention.[J].Urology,1974,3(3):345-347.
[15]Muruganandham K, Dubey D, Kapoor R. Acute urinary retention in benign prostatic hyperplasia:Risk factors and current management.[J]. Indian J Urol,2007, 23(4):347-353.
[16]Thorne M B, Geraci S A. Acute urinary retention in elderly men.[J]. Am J Med,2009,122(9):815-819.
[17]Roehrborn C G, Bruskewitz R, Nickel G C, et al. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group.[J]. Eur Urol,2000,37(5):528-536.
[18]Emberton M, Cornel E B, Bassi P F, et al. Benign prostatic hyperplasia as a progressive disease:a guide to the risk factors and options for medical management. [J]. Int J Clin Pract,2008,62(7):1076-1086.
[19]Marberger M J, Andersen J T, Nickel J C, et al. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials.[J]. Eur Urol, 2000,38(5):563-568.
[20]牛海涛,张勤,赵伟.良性前列腺增生并发急性尿储留的风险因素预测以及临床意义.[J].中华泌尿外科杂志,2007,28(6)：407-410.
[21]Roehrborn C G, Mcconnell J D, Saltzman B, et al. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes.[J]. Eur Urol,2002,42(1):1-6.
[22]Roehrborn C G, Mcconnell J D, Lieber M, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.[J]. Urology,1999,53(3):473-480.
[23]任宝明,何士军,马龙,等.良性前列腺增生症发生急性尿潴留的相关因素分析[J].临床泌尿外科杂志,2007,22(11)：856-857.
[24]Taube M, Gajraj H. Trial without catheter following acute retention of urine.[J]. Br J Urol,1989,63(2):180-182.
[1]Blumenfeld W, Tucci S, Narayan P. Incidental lymphocytic prostatitis. Selective involvement with nonmalignant glands [J]. Am J Surg Pathol,1992,16(10):975-981.
[2]Gerstenbluth RE, Steftel AD, MacLennan GT, et al. Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of Bcl-2 in areas of inflammation[J]. J Urol,2002,167(5):2267-2270.
[3]Collins MM,Meigs JB,Barry MJ,et al.Prevalence and correlates of prostatitis in the health professionals follow-up study cohort [J].J Urol,2002,167(3):1363-1366.
[4]St Sauver JL, Jacobson DJ, McGree ME, et al. Longitudinal association between prostatitis and development of benign prostatic hyperplasia[J]. Urology,2008,71(3): 475-479.
[5]宁夏,时景璞,吴作艳,等.沈阳农村60岁以上人群良性前列腺增生危险因素的病例对照研究[J].中华流行病学杂志,2003,24(4)：276-280.
[6]那彦群.中国泌尿外科疾病诊断治疗指南(2007版)[M].北京：人民卫生出版社,2007：215-219.
[7]Krieger JN, Nyberg LJ, Nickel JC. NIH consensus definition and classification of prostatitis [J]. JAMA,1999,282(3):236-237.
[8]Benson MC. Prostate specific antigen density:a means of distinguishing benign prostatic hyperplasia and prostate cancer [J]. J Urol,1992,147(3):815-816.
[9]华立新,吴宏飞,眭元庚,等.移行区指数作为良性前列腺增生的预测指标[J].南京医科大学学报,2003,23(4)：365-366.
[10]陈业宗,崔强.保列治联合高特灵治疗良性前列腺增生合并慢性前列腺炎的疗效观察[J].医学临床研究,2007,24(5)：818-820.
[11]Theyer G, Kramer G, Assmann I, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia[J]. Lab invest,1992,66 (1): 99-107.
[12]Roehrborn CG, Kaplan SA, Noble WD, et al. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH:results from the MTOPS study[R]. American Urological Association 2005 Moderated Poster, May 24,2005.
[13]夏同礼.良性前列腺增生与前列腺炎的关系值得深入研究[J].中华男科学,2004,10(2)：83-85.
[14]段义星,杨罗艳.前列腺炎和良性前列腺增生症[J].国外医学泌尿系统分册,2004,24(2)：198-202.
[15]Jason PG, Oliver P, Megan D, et al. The role of prolactin in the prostatic inflammatory response to neonatal estrogen[J]. Endocrinology,2003,144(5):2046-2054.
[16]Fromont G, Chene L, Latil A, et al. Molecular profiling of benign prostatic hyperplasia using a large scale real-time reverse transcriptase-polymerase chain reaction approach[J]. J Urol,2004,172(4):1382-1385.
[17]Nickel JC, Roehrborn CG, O'Leary M, et al. Examination of the relationship between symptoms of prostatitis and histological inflammation:baseline data from the REDUCE chemoprevention trial[J]. Urol,2007,178(3 Pt 1):896-900.
[18]Nickel JC. Inflammation and Benign Prostatic Hyperplasia[J]. Urol Clin N Am, 2007,35(1):109-115.
[19]Rowe E, Smith C, Laverick L, et al. A prospective, randomized, placebo controlled, double-blind study of pelvic electromagnetic therapy for the treatment of chronic pelvic pain syndrome with 1 year of followup[J]. J Urol,2005,173(6): 2044-2047.
[20]Shahed AR, Shoskes DA. Correlation of beta-endorphin and prostaglandin E2 levels in prostatic fluid of patients with chronic prostatitis with diagnosis and treatment response[J].J Urol,2001,166(5):1738-1741.
[21]Hussain T, Gupta S, Mukhtar H. Cyclooxygenase and prostate carcinogenesis [J]. Cancer Lett,2003,191(2):125-135.
[22]Anim JT, Udo C, John B. Characterization of inflammatory cells in benign prostatic hyperplasia[J]. Acta Histochem,1998,100(4):439-449.
[23]Kravchick S, Cytron S, Agulansky L, et al. Acute prostatitis in middle-aged men: a prospective study [J]. BJU Int,2004,93(1):93-96.
[24]Mochtar CA, Kiemeney LA, Van Riemsdijk MM, et al. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia[J]. Eur Urol,2003,44(6):695-700.
[25]Kwak C, Ku JH, Kim T, et al. Effect of subclinical prostatic inflammation on serum PSA levels in men with clinically undetectable prostate cancer[J]. Urology, 2003,62:854-859.
[26]Di Silverio F, Gentile V, DeMatteis A, et al. Distributi on of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia:A retrospective analysis [J]. Eur Urol,2003,43:164-175.
[27]Hasui Y, Marutsuka K, Asada Y, et al. Relationship between serum prostate-specific antigen and histological prostatitis in patients with benign prostatic hyperplasia [J].Prostate,1994,25:91-96.
[28]Yaman O, Gogus C, Tulunay O, et al. Increased prostate-specific antigen in subclinical pr ostatitis:The role of aggressiveness and extension of inflammation [J]. Urol Int,2003,71:160-167.
[29]Ozden C, Ozdal OL, Guzel O, et al. The correlation between serum prostate specific antigen levels and asymptomatic inflammatory prostatitis[J]. Int Urol Nephrol, 2007,39:859-863.
[30]Stancik I, Luftenegger W, Klimpfinger M, et al. Effect of NIH-IV prostatitis on free and free-to-total PSA [J]. Eur Urol,2004,46:760-764.
[31]McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxaxosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia[J]. N Engl J Med,2003,349(25):2387-2398.
[32]席志军,宁新荣,郝金瑞,等.前列腺增生症PSA、PSAD与患者的年龄、前列腺体积的关系[J].中华外科杂志,2001,39(2)：170.
[33]Koseoglu DR, Erdemir F, Parlaktas BS. Effect of chronic prostatitis on angiogenic activity and serum prostate specific antigen level in benign prostatic hyperplasia[J]. Kaohsiung J Med Sci,2007,23(8):387-394.
[1]Roehrbom CG, Mc Connell JD. Etiology, pathothysiology, epidemiology and natural history of binign prostatic hyperplasia In:PC Walsh, AB, Retik, ED Vanghan, Jr and AJ Wein. Campbell's Urology. Philadelphia, PA:W.B.Sanndcrs Company, 2002,chapt 38:1297-1330.
[2]Berry MJ, Coffey DS, Walsg PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol,1984,132:474-478.
[3]Gu fl, Xia TL, Kong XT. Preliminary study of the frequency of benign prostatic hyperplasia and prostatic cancer in china. Urology,1994,44:688-691.
[4]Zwergel U, WullichB, Lindenmeir U, et al. Long-term results flowing transurethral resection of the prostate. Eur Urol,1998, (5):476-480.
[5]Saad F, Carrier S, Jolivet-Tremblay M. Comparison of prostatic electrovap-orization and transurethral resection in the treatment of benign prostatic Hypertrophy. Ann Clair,1997,51(8):884-886.
[6]Borborglu PG, Kant CJ, WardJF, et al. Immediate and postoperative complications of transurethral prostatectomy in 1990s. J Urol,1999,162:1307-1310.
[7]Wason JH, Reda DJ, Bruskewitz RC, et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group On Transurethral Resection of the Prostate. New Engl J Med,1995,332:75-79.
[8]Talic RF. Transurethml vaporization-resection of the prostate using Wing cutting electrode:preliminary results of safety and efficacy in the treatment of men with prostatic outflow obstruction. Urology,1999,53(1):106-110.
[9]Cetinkaya ME,Ulnsoy O, adsan H, et al. Comparative early results of transurethral electroresection and transurethral electrovaporizafion in benign prostatic hyperplasia. BJU,1996,78:901-903.
[10]Mebnst WK. Transurethul surgery. In:Walsh PC,Rctok AB, Vaughan ED, Wein AJ, eds. Campbell's urology. Vol 2.8th ed. Philadelphia:Saunders,2003, 1479-1505.
[11]那彦群.中国泌尿外科疾病诊断治疗指南(2007版)[M].北京：人民卫生出版社,2007：215-219.
[12]Benson MC. Prostate specific antigen density:a means of distinguishing benign prostatic hyperplasia and prostate cancer [J]. J Urol,1992,147(3):815-816.
[13]华立新,吴宏飞,眭元庚,等.移行区指数作为良性前列腺增生的预测指标[J].南京医科大学学报,2003,23(4)：365-366.
[14]Mc Cormell JD, Roehrbom CG, Banstita OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. NEengl J Med 2003; 349:2387-2398.
[15]Hon NH, Brathwaite D, Hussain z, et al. A prospective randomized trial comparing conventional transurethral prostate resection with Plasma Kinetic vaporization of the prostate:physiological changes, early complications and long-term followup[J]. J Urol,2006,176(1):205-209.
[16]Ekengren J, Hahn RG. Complications during transurethral vaporization of the prostate. Urology,1996,48(3):424-427.
[17]Cetinlmya ME, Ulusoy O, Adsan H, et al. Comparative early results of transurethral electroreseetion and transurethral electrovaporization in benign prostatic hyperplasia. Br J Urol,1996,78:901-903.
[18]Mcalister WJ, Karim V, Plail RO, et al. Transurethral vaporization of the prostate:is it any better than conventional transurethral resection of the prostate? BJU int,200,91(3):211-214.
[19]Mebust WK, Holtgrewe HL, Coekett ATK, et al. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 anticipating institutions evaluating 3885 patients. J Urol,1989,141:243-247.
[20]周兴,刘春晓,郑少波.经尿道前列腺汽化切割治疗前列腺增生症(附560例报告)[J].中国内镜杂志,2000,6(2)：11-12.
[21]Cetinkaya M, Ulusoy E, Adson O, et al. Comparative early results of transurethral electroresection and transurethral electrovaporisation in benign prostatic hyperplasia[J]. Br Uro l,1996,78:902-903.
[22]毛全宗,荣石,李汉忠,等.良性前列腺增生经尿道前列腺电切术后再次电切手术的临床分析[J].中华医学杂志,2004,84：372-374.
[23]张伦中,李解方,何书华,等.经尿道前列腺等离子双极汽化术与经尿道前列腺单极汽化术治疗高危前列腺增生的临床对比研究[J].中国内镜杂志,2006,4(12)：378-382.
[1]Abrams P. New words for old:lower urinary tract symptoms for 'prostatism'.[J]. BMJ,1994;69:929-30.
[2]Abrams P. LUTS, BPH, BPE, BPO:A Plea for the Logical Use of Correct Terms.[J]. Rev Urol,1999;1(1):65.
[3]Garraway Wm, Collins Gn LR. High prevalence of benign prostatic hypertrophy in the community.[J]. Lancet,1991;338(8765):469-71.
[4]Rm S. Lower urinary tract symptoms (LUTS):what are the implications for the patients?[J]. Eur Urol,2001;40((suppl 4)):10-20.
[5]Kakizaki H, Matsuura S, Mitsui T, Ameda K, Tanaka HKT. Questionnaire analysis on sex difference in lower urinary tract symptoms.[J]. Urology,2002; 59(1): 58-62.
[6]Schatzl G, Temml C, Waldmuller J, Thurridl T, Haidinger GMS. A comparative cross-sectional study of lower urinary tract symptoms in both sexes.[J]. Eur Urol,2001;40(2):213-19.
[7]Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia.[J]. Rev Urol,2004;6 Suppl 9:3-10.
[8]Elbadawi A, Diokno Ac MR. The aging bladder:Morphology and urodynamics. [J]. World J Urol,1998;16((suppl 1)):10-34.
[9]Fultz Nh HA. Epidemiology of urinary symptoms in the geriatric population.[J]. Urol Clin North Am,1996;23(1-10).
[10]Jg M. The prostate gland:morphology and pathobiology.[J]. Monogr Urol.,1983;4:3-33.
[11]Berry Sj, Coffey Ds, Walsh Pc E L. The development of human benign prostatic hyperplasia with age.[J]. J Urol.1984 Sep;132(3):474-9,1984;132(3):474-79.
[12]Jepsen Jv BR. Office evaluation of men with lower urinary tract symptoms.[J]. Urol Clin North Am.,1998;25(4):545-54.
[13]C C. Clinical study of benign prostatic disease, current concepts and future prospects:randomized controlled trials versus real life practice.[J]. Curr Opin Urol.,2003;13(1):1-5.
[14]Berry S J, Coffey D S, Walsh P C, et al. The development of human benign prostatic hyperplasia with age[J]. J Urol,1984; 132(3):474-79.
[15]Barry M J, Fowler F J, Bin L, et al. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists.[J]. J Urol,1997;157(1):10-45.
[16]Meigs J B, Mohr B, Barry M J, et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men.[J]. J Clin Epidemiol,2001;54(9):935-44.
[17]Trueman P, Hood Sc, Nayak Us M M. Prevalence of lower urinary tract symptoms and self-reported diagnosed'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK.[J]. BJU Int,1999;83(4):410-15.
[18]Verhamme K M, Dieleman J P, Bleumink G S, et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project.[J]. Eur Urol,2002;42(4):323-28.
[19]Horchani A, Binous MY, Ben HA, et al. [Prevalence of benign prostatic hyperplasia in general practice and practical approach of the Tunisian general practitioner (Prevapt study)][J]. Tunis Med,2007;85(8):619-24.
[20]Berges R. [Epidemiology of benign prostatic syndrome:Associated risks and management data in German men over age 50.][J]. Urologe A,2008;47(2):141-48.
[21]Homma Y, Kawabe K, Tsukamoto T, et al. Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the international prostate symptom score[J]. Int J Urol,1997;4(1):40-46.
[22]Lowe F C, Batista J, Berges R, et al. Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion.[J]. Prostate Cancer Prostatic Dis,2005; 8(3): 206-9.
[23]Fitzpatric JM. The natural history of benign prostatic hyperplasia.[J]. BJU Int, 2006,97(Suppl 2):3-6.
[24]Jacobsen S J, Girman C J, Lieber M M. Natural history of benign prostatic hyperplasia.[J]. Urology,2001;58(6 Suppl 1):5-16.
[25]Roehrborn C G. BPH progression:concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.[J]. BJU Int.,2008; 101 (Suppl 3):17-21.
[26]Emberton M, Zinner N, Michel M C, et al. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia:therapeutic options for the man at risk.[J]. BJU Int,2007;100(2):249-53.
[27]Fong Yk, Milani S D B. Natural history and clinical predictors of clinical progression in benign prostatic hyperplasia.[J]. Curr Opin Urol.,2005;15(1):35-38.
[28]Gup D I, Shapiro E, Baumann M, et al. Contractile properties of human prostate adenomas and the development of infravesical obstruction.[J]. Prostate,1989,15(2): 105-14.
[29]Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia.[J]. N Engl J Med.,1987;317(10):599-4.
[30]Kutikov A, Guzzo T J, Malkowicz S B. Clinical approach to the prostate:an update.[J]. Radiol Clin North Am,2006;44(5):649-63.
[31]Lepor H, Tang R, Kobayashi S, et al. Localization of the alpha 1A-adrenoceptor in the human prostate.[J]. J Urol,1995;154(6):2096-99.
[32]Lepor H, Tang R, Shapiro E. The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle.[J]. Prostate,1993;22(4):301-7.
[33]Walden P D, Gerardi C, Lepor H. Localization and expression of the alphalA-1, alphalB and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate.[J]. J Urol,1999;161(2):635-40.
[34]Levin R M, Levin S S, Zhao Y, et al. Cellular and molecular aspects of bladder hypertrophy.[J]. Eur Urol,1997;32 Suppl 1:15-21.
[35]Thomas A W, Abrams P. Lower urinary tract symptoms, benign prostatic obstruction and the overactive bladder.[J]. BJU Int,2000;85 Suppl 3:57-1.
[36]Knutson T, Edlund C, Fall M, et al. BPH with coexisting overactive bladder dysfunction--an everyday urological dilemma.[J]. Neurourol Urodyn,2001,20(3): 237-47.
[37]Andersson K E. Storage and voiding symptoms:pathophysiologic aspects.[J]. Urology,2003;62(5 Suppl 2):3-10.
[38]Levin R M, Haugaard N, O C L, et al. Obstructive response of human bladder to BPH vs. rabbit bladder response to partial outlet obstruction:a direct comparison.[J]. Neurourol Urodyn,2000; 19(5):609-29.
[39]Nevel-mcgarvey C A, Levin R M, Haugaard N, et al. Mitochondrial involvement in bladder function and dysfunction.[J]. Mol Cell Biochem,1999,194 (1-2):1-15.
[40]Steers W D, Clemow D B, Persson K, et al. The spontaneously hypertensive rat: insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males.[J]. Exp Physiol,1999;84(1):137-47.
[41]Chai T C, Andersson K E, Tuttle J B, et al. Altered neural control of micturition in the aged F344 rat.[J]. Urol Res,2000;28(5):348-54.
[42]Isaacs J T. Etiology of benign prostatic hyperplasia. [J]. Eur Urol,1994;25 Suppl 1:6-9.
[43]Colombel M, Vacherot F, Diez S G, et al. Zonal variation of apoptosis and proliferation in the normal prostate and in benign prostatic hyperplasia.[J]. Br J Urol,1998;82(3):380-85.
[44]Marcelli M, Cunningham G R. Hormonal signaling in prostatic hyperplasia and neoplasia.[J]. J Clin Endocrinol Metab,1999;84(10):3463-68.
[45]Mcconnell J D. Benign prostatic hyperplasia. Hormonal treatment.[J]. Urol Clin North Am,1995;22(2):387-0.
[46]Roberts R O, Jacobson D J, Rhodes T, et al. Serum sex hormones and measures of benign prostatic hyperplasia. [J]. Prostate,2004;61 (2):124-31.
[47]Prins G S, Korach K S. The role of estrogens and estrogen receptors in normal prostate growth and disease.[J]. Steroids,2008;73(3):233-44.
[48]Smith P, Rhodes N P, Ke Y, et al. Relationship between upregulated oestrogen receptors and expression of growth factors in cultured, human, prostatic stromal cells exposed to estradiol or dihydrotestosterone.[J]. Prostate Cancer Prostatic Dis,2004;7(1):57-62.
[49]Partin A W, Oesterling J E, Epstein J I, et al. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. [J]. J Urol,1991;145(2):405-9.
[50]Roberts R O, Jacobson D J, Rhodes T, et al. Serum sex hormones and measures of benign prostatic hyperplasia.[J]. Prostate,2004;61(2):124-31.
[51]Nickel J C. Inflammation and benign prostatic hyperplasia.[J]. Urol Clin North Am,2008;35(1):109-15.
[52]Mishra V C, Allen D J, Nicolaou C, et al. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia?[J]. BJU Int,2007;100(2):327-31.
[53]Wang L, Yang J R, Yang L Y, et al. [Expression of Ki-67,Bcl-2,Bax and caspase-3 in benign prostatic hyperplasia combined with prostatitis and their significances.][J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban,2008;33(3):222-26.
[54]Penna G, Mondaini N, Amuchastegui S, et al. Seminal plasma cytokines and chemokines in prostate inflammation:interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia.[J]. Eur Urol,2007;51(2):524-33.
[55]Nickel J C. Inflammation and benign prostatic hyperplasia.[J]. Urol Clin North Am,2008;35(1):109-15.
[56]Steiner G, Gessl A, Kramer G, et al. Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia.[J]. J Urol,1994;151(2):480-84.
[57]Kramer G, Steiner G E, Handisurya A, et al. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation.[J]. Prostate,2002;52(1):43-58.
[58]Steiner G E, Stix U, Handisurya A, et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue.[J]. Lab Invest,2003;83(8):1131-46.
[59]Rohrmann S, De M A, Smit E, et al. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES Ⅲ).[J]. Prostate,2005;62(1):27-33.
[60]Konig J E, Senge T, Allhoff E P, et al. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer.[J]. Prostate,2004;58(2):121-29.
[61]Castro P, Xia C, Gomez L, et al. Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia.[J]. Prostate,2004;60(2):153-59.
[62]Taoka R, Tsukuda F, Ishikawa M, et al. Association of prostatic inflammation with down-regulation of macrophage inhibitory cytokine-1 gene in symptomatic benign prostatic hyperplasia.[J]. J Urol,2004;171(6 Pt 1):2330-35.
[63]Yun A J, Doux J D. Opening the floodgates:benign prostatic hyperplasia may represent another disease in the compendium of ailments caused by the global sympathetic bias that emerges with aging.[J]. Med Hypotheses,2006;67(2):392-94.
[64]Mcvary K T, Rademaker A, Lloyd G L, et al. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.[J]. J Urol,2005; 174(4 Pt 1):1327-33.
[65]Partin J V, Anglin I E, Kyprianou N. Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction.[J]. Br J Cancer,2003;88(10):1615-21.
[66]Dinh D T, Frauman A G, Somers G R, et al. Evidence for activation of the renin-angiotensin system in the human prostate:increased angiotensin II and reduced AT(1) receptor expression in benign prostatic hyperplasia. [J]. J Pathol,2002; 196(2): 213-19.
[67]Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?[J]. Eur Urol,2007;51(5):1202-16.
[68]Yokota T, Honda K, Tsuruya Y, et al. Functional and anatomical effects of hormonally induced experimental prostate growth:a urodynamic model of benign prostatic hyperplasia (BPH) in the beagle.[J]. Prostate,2004;58(2):156-63.
[69]Olapade-olaopa E O, Moscatello D K, Mackay E H, et al. A variant epidermal growth factor receptor protein is similarly expressed in benign hyperplastic and carcinomatous prostatic tissues in black and white men.[J]. West Afr J Med,2007, 26(1):42-47.
[70]Eaton C L. Aetiology and pathogenesis of benign prostatic hyperplasia. [J]. Curr Opin Urol,2003;13(1):7-10.
[71]Lee K L, Peehl D M. Molecular and cellular pathogenesis of benign prostatic hyperplasia.[J]. J Urol,2004; 172(5 Pt 1):1784-91.
[72]Mirone V, Imbimbo C, Longo N, et al. The detrusor muscle:an innocent victim of bladder outlet obstruction. [J]. Eur Urol,2007;51(1):57-66.
[73]Levin R, Chichester P, Levin S, et al. Role of angiogenesis in bladder response to partial outlet obstruction.[J]. Scand J Urol Nephrol Suppl,2004(215):37-47.
[74]Pearson J D, Lei H H, Beaty T H, et al. Familial aggregation of bothersome benign prostatic hyperplasia symptoms.[J]. Urology,2003;61(4):781-85.
[75]Mcvary K. Lower urinary tract symptoms and sexual dysfunction:epidemiology and pathophysiology.[J]. BJU Int,2006;97 Suppl 2:23-45.
[76]Ikuerowo S O, Akindiji Y O, Akinoso O A, et al. Association between erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia in Nigerian men.[J]. Urol Int,2008;80(3):296-99.
[77]Braun M H, Sommer F, Haupt G, et al. Lower urinary tract symptoms and erectile dysfunction:co-morbidity or typical "Aging Male" symptoms? Results of the "Cologne Male Survey".[J]. Eur Urol,2003;44(5):588-94.
[78]Seim A, Hoyo C, Ostbye T, et al. The prevalence and correlates of urinary tract symptoms in Norwegian men:the HUNT study.[J]. BJU Int,2005;96(1):88-92.
[79]Holden C A, Jolley D J, Mclachlan R I, et al. Men in Australia Telephone Survey (MATeS):predictors of men's help-seeking behaviour for reproductive health disorders.[J]. Med J Aust,2006;185(8):418-22.
[80]Ponholzer A, Temml C, Mock K, et al. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire.[J]. Eur Urol,2005,47(1): 80-56.
[81]Li M K, Garcia L, Patron N, et al. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.[J]. BJU Int,2008;101(2):197-2.
[82]Ikuerowo S O, Akindiji Y O, Akinoso O A, et al. Association between erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia in Nigerian men.[J]. Urol Int,2008;80(3):296-99.
[83]Ozayar A, Zumrutbas A E, Yaman O. The relationship between lower urinary tract symptoms (LUTS), diagnostic indicators of benign prostatic hyperplasia (BPH), and erectile dysfunction in patients with moderate to severely symptomatic BPH.[J]. Int Urol Nephrol,2008.
[84]Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction:the multinational survey of the aging male (MSAM-7).[J]. Eur Urol,2003;44(6):637-49.
[85]Chang S, Hypolite J A, Zderic S A, et al. Increased corpus cavernosum smooth muscle tone associated with partial bladder outlet obstruction is mediated via Rho-kinase.[J]. Am J Physiol Regul Integr Comp Physiol,2005;289(4):1124-30.
[86]Khan M A, Thompson C S, Dashwood M R, et al. Endothelin-1 and nitric oxide in the pathogenesis of urinary tract disorders secondary to bladder outlet obstruction.[J]. Curr Vasc Pharmacol,2003;1(1):27-31.
[87]Lowe F C. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia:sexual function.[J]. BJU Int,2005;95 Suppl 4:12-18.
[88]Carson C C. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia:treatments of lower urinary tract symptoms, erectile dysfunction, or both?[J]. BJU Int,2006;97 Suppl 2:39-45.
[89]Demir O, Murat N, Asian G, et al. Effect of doxazosin with and without rho-kinase inhibitor on human corpus cavernosum smooth muscle in the presence of bladder outlet obstruction.[J]. J Urol,2006;175(6):2345-49.
[90]Gonzalez R R, Kaplan S A. Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.[J]. Expert Opin Drug Metab Toxicol,2006;2(4):609-17.
[91]Mcvary K T, Kaufman J, Young J M, et al. Sildenafil citrate improves erectile function:a randomised double-blind trial with open-label extension.[J]. Int J Clin Pract,2007;61(11):1843-49.
[92]Kaplan S A, Gonzalez R R, Te A E. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.[J]. Eur Urol,2007;51 (6):1717-23.
[93]Stief C G, Porst H, Neuser D, et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.[J]. Eur Urol,2008; 53(6): 1236-44.
[94]Djavan B. Guidelines on benign prostatic hyperplasia:where do we stand in the new millennium?[J]. Curr Urol Rep.2002 Apr;3(2):91-2.,2002;3(2):91-92.
[95]那彦群.中国泌尿外科疾病诊断治疗指南[M].1 ed.北京：人民卫生出版社,2007：167-4.
[96]Jepsen J V, Bruskewitz R C. Office evaluation of men with lower urinary tract symptoms.[J]. Urol Clin North Am,1998;25(4):545-54.
[97]Barry M J. Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia.[J]. Urology,2001;58(6 Suppl 1):25-32.
[98]Weiss J P, Blaivas J G, Tash A J, et al. Development and validation of a new treatment outcome score for men with LUTS.[J]. Neurourol Urodyn,2004; 23(2): 88-93.
[99]Speakman M J, Kirby R S, Joyce A, et al. Guideline for the primary care management of male lower urinary tract symptoms.[J]. BJU Int,2004;93(7):985-90.
[100]Barry M J, Fowler F J, O L M, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.[J]. J Urol,1992;148(5):1549-64.
[101]Donovan J L. Use of symptom questionnaires in the assessment and follow-up of men with benign prostatic disease.[J]. Curr Opin Urol,1999;9(1):3-7.
[102]Peters T J, Donovan J L, Kay H E, et al. The International Continence Society "Benign Prostatic Hyperplasia" Study:the botherosomeness of urinary symptoms.[J]. J Urol,1997;157(3):885-89.
[103]Netto N R, De L M, Netto M R, et al. Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting.[J]. Urology,1999;53(2):314-16.
[104]Spatafora S, Conti G, Perachino M, Casarico A, Mazzi G P G, A I B G C. Evidence-based guidelines for the management of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy:updated summary.[J]. Curr Med Res Opin.,2007;23(7):1715-32.
[105]Harkaway R C, Issa M M. Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia. [J]. Prostate Cancer Prostatic Dis,2006; 9(3): 204-14.
[106]Price D. Potential mechanisms of action of superselective alpha(1)-adrenoceptor antagonists.[J]. Eur Urol,2001;40 Suppl 4:5-11.
[107]Levy A, Samraj G P. Benign prostatic hyperplasia:when to'watch and wait,' when and how to treat.[J]. Cleve Clin J Med,2007;74 Suppl 3:15-20.
[108]Roehrborn C G. Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia:achievements and limitations.[J]. Rev Urol,2008;10(1):14-25.
[109]Nix J W, Carson C C. Medical management of benign prostatic hypertrophy. [J]. Can J Urol,2007;14 Suppl 1:53-57.
[110]Stief C G, Porst H, Neuser D, et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.[J]. Eur Urol,2008; 53(6):1236-44.
[111]Kaplan Sa, Roehrborn Cg, Chancellor M, Carlsson M, Bavendam T G Z. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder:effects on urinary symptoms assessed by the International Prostate Symptom Score.[J]. BJU Int.,2008.
[112]Andersson K E. LUTS treatment:future treatment options.[J]. Neurourol Urodyn,2007;26(6 Suppl):934-47.
[113]Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia.[J]. Rev Urol,2007;9(4):181-90.
[114]Mcvary K T. A review of combination therapy in patients with benign prostatic hyperplasia.[J]. Clin Ther,2007;29(3):387-98.
[115]Gallegos P J, Frazee L A. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.[J]. Pharmacotherapy,2008; 28 (3):356-65.
[116]Blake-james B T, Rashidian A, Ikeda Y, et al. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia:a systematic review and meta-analysis.[J]. BJU Int,2007;99(1):85-96.
[117]Andersson K E, Uckert S, Stief C, et al. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS.[J]. Neurourol Urodyn,2007;26(6 Suppl):928-33.
[118]Gur S, Kadowitz P J, Hellstrom W J. Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction:implications for sexual dysfunction.[J].Drugs,2008;68(2):209-29.
1. Guess HA, ArrighiHM, MetterEJ, et al. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate 1990; 17: 241-246
2.万少平,胡礼泉,刘源.武汉市2811例男性下尿路症状问卷调查.中华泌尿外科杂志,2004,25：585-587
3. Walsh PC, Hutehins GM, Ewing LL. Tissue content of dihydrotestosterone in human prostatic hyperplasis is not supranormal. J Clin Invest,1983,72:1772-1777
4. Steers WD.5 alpha-reductase activity in the Porsate. Uorlogy,2001,58:17-24
5. McConell JD, Wilson JD, Gerogre FW, et al. Finasteirde, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign Prostatic hyperplasia. J Clin Endocrinal Metav,1992,74:505-508
6. Nomran RW, Coakes KE, Wright AS. Meatbolism in men receiving finasteride before prostatectomy. J Urol,1993,150:1736-173
7. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med,1992,327:1185-1191
8. MeConnell JD, Bruskewitz MD, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med,1998,338:557-563
9. McCoenll JD, Reginald B, Whlsh P, et al. The effect of finasteirde on the risk of acute urinary retention and he need for surgical treatment among men with benign prostatic hyperplasia. N Engle J Med,1998,338:557-563
10. Lowe FC, MeConnell JD, Hudson PB, et al. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology,2003,61:791-796
11. Kaplan S, Holtgrewe H, Bruskewitz R, et al. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology,2001,57:1073-1077
12. Mcconnde JD. Finasteride, An inbibiter of 5α-redctase suppresses prostatic, dihydrotestosterone in men with benign Prostatic hyperplasia. J Clin Endocrinol Metab,1992:74:505
13. Herbert L. The efficacy of terazosin finasterideor both in benign prostatic hyperplasia. N Engl Med,1996,335(8):533
14.酒井英树.前列腺肥大的内分泌治疗.日本医学介绍,1997,18(10)：470
15. Andriole G, Bostwick D, Brawley O, et al. Chemoprevention of prostate cancer in man at high risk:rationale and design of the reduction by dutasteride of prostate ca ncer events (REDUCE) trial. J Urol,2004,172:1314-1317
16. Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benigh prostatic hyperplasia. Urology,2002,60:434-441
17. O'leary MP, Roehrborn C, Andriole G, et al. Improvements in benigh prostatic hyperplasia specific quality of life with dutasteride, the novel dual 5a-reductase inhibitor. BJU Inter,2003,92:262-266
18. Chapple CR. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms:an over view for the Practising clinician. BJU Int,2004,94: 738-744
19. Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology,2004,63: 709-715
20. Lepor H, Tang R, Shapiro E. The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle. Prostate,1993,22(4):301-307.
21. Walden PD, Gerardi C, Lepor H. Localization and expression of the alphalA-1 alpha1B, alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. J Urol,1999,161(2):635-640
22. Muramatsu I, Taniguchi T, Okada K. Tamsulosin:alphal adrenoceptor subtype-selectivity and comparison with terazosin. Jpn J Pharmacol,1998,78(3): 331-335
23. Kyprianou N, Litvak JP, Borkowski A, et al. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol,1998,159(6):1810-1815
24. Taniguchi N, Ukai Y, Tanaka T, et al. Identification of alpha 1-a-drenoceptor subtypes in the human prostatic urethra. Naunyn Schmiedebergs Arch Pharmacol, 1997,355(3):412-416
25. Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha-1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol,2003,170(2 Pt 1):649-653
26. Yamamoto T, Ghosh R, De Groat WC, et al. Facilitation of transmitter release in the urinary bladders of neonatal and adult rats via alphal-a-drenoceptors. Eur J Pharmacol,2001,414(1):31-35
27. Yashiyama M, De Groat WC. Role of spinal alpha1-adrenoceptor subtypes in the bladder reflex in anesthetized rats. Am J Physiol Regul Integr Comp Physiol, 2001,280(5):R1414-1419
28. Chapple CR. Pharmacotherapy for benign prostatic hyperplasia the potential for al-adrenoceptor subtype specific blockade. Br J Urol,1998,81:34-47
29. Hayashi T, Sakai Y, Saito K, et al. A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia. Hinyokika Kiyo,2002,48(1):7-11
30. Lepor H, Jones K, Williford W. The mechanism of adverse events associated with terazosin:an analysis of the Veterans Affairs cooperative study. J Urol,2000, 163(4):1134-1137
31.Iepor H, Jones K, Williford W. The mechanism of adverse events associated with terazosin:an analysis of the Veterans Affairse operative study. J Urol,2000,163: 1134-1137
32. Michel MC, Flannery MT, Narayan P. Worldwide experience with alfuzosin and tamsulosin. Urology,2001,58(4):508-516
33. Lepor H, WillifodrE, KontuirM, et al. The efficacy of terazosin, finasterider, or both in benign Prostatic hyperplasia.Veterans Afeirs Cooperative Studies Benign Prostatic Hyperplasia Study GrouP. N Engl J Med,1996,335(8):533-539
34. Bautisatom, Kusek JW, Nbyegr LM, et al. Study design of the medical therapy of prostatic symptoms (MTOP) trail. Control Clin Trail,2003,24:224-243
35. McConell JD, Roellrborn CG, Batuista OM, et al. The long-term effect of coxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med,2003,349:2387-2398
36. Athanasopoulos A, Gyftopoulos K, Giannitasa K, et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction:a prospective, randomized, controlled study. Urology,2003,169(60):2253-2256
37. Yarker Y, Goa KL, Fitton A. Oxybutytnin:A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drug Aging, 1995,6(3):243-262
38. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder:results of the object study. Mayo Clin Proc,2001,76(4): 358-3613
39. Davila GW, Daugherty CA,Sanders SW. A shortterm, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate realease oral oxybutynin treatment of patents with urge urinary incontinence. J Urol,2001,166(1):140-145
40. Nilvebrant L, Andersson KE, Gillberg PG, et al. Tolterodine a new bladder-selective antimuscarinic agent. Eur J Pharmacol,1997; 327:195-207
41.吴士良,杨勇,薛兆英,等.新型抗胆碱能药物托特罗定治疗膀胱过度活动症的临床研究.中华泌尿外科杂志,2001；22(4)：217-219
42. Postlind H, Danielson A, Lindgren A, et al. Tolterodine, a novel muscarinic receptor antagonist, ismetabolized by cytochromes P450 2D6 and 3A4 in human liver microsomes. Drug Metab Dispos,1998,26(4):289-293
43. Brynne N, Aperia B, AbergWistedt A, et al. Inhibition of tolterodine metabolism by fluoxetine w ith minor change in antimuscarinic activity. Eur J Clin Pharmacol, 1997,52 Suppl:A 1301
44. Chancellor M, Freedaman S, Mitcheson HD. Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clin Drug Invest,2000,19(2):83-91
45. Messelink EJ. Treatment of the overactive bladder with tolterodine, a new muscarinic receptor antagonist. BJU International,1999,83 Suppl2:48-52
46. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder:a pooled analysis. Urology,1997,50 (6A Suppl):90-96
47. Stohrer M, Bauer P, Giannetti BM. Effect of t rospium chloride on urodynamic parameters in patient s with detrusor hyperreffexia due to spinal cord injuries. Urol Int,1991-ncbi. nlm. nih. gov
48. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol,2004,172(5Pt1):1919-1924
49.罗景慧,杨迎暴.曲司氯铵-治疗伴有急迫性症状的膀胱过度活动症的新药.中国新药与临床杂志,2006,25(6)：466-469
50. Schladitzkeil G, Spahn H, Mutschler E. Determination of t he bioavailability of the quaternary compound trospiu chloride in man from urinary excretion data. Arzneimittelforsch,1986,6(6):984-987
51. Sandage B, Najarian N, Lasseter K. The effect of hepatic disease on the pharmacokinetics of t rospium chloride [C]//Program and Abstract s of the Annuel Metting of the International Continence Society. Paris, France:Indevus Pharmaceuticals Inc,2004:584
52. Stohrer M, Bauer P, Glannetti BM, et al. Effect of trospium chloride on urodynamic parameters in patient s wit h det rusor hyperreflexia due to spinal cord injuries. Amulticent re placebo2cont rolles double-blind trial. Urol Int,1991,47(3): 138-143
53. Todorova A, Vendeheid-Guth B, Dimofel W. Tolterodine, trospium chloride and oxybynin on t he central nervous system. J Clin Pharmacol,2001,40(16):636-644
54. Gerber GS. Saw palmetto for the treatment of men with lower urinary tract symptoms. J Urol,2000,163:1408-1412
55. Al-Shukri, Deschaseaux P, Kuzmin IV, et al. Early urodynamic effects of lipidosterolic extract of Serenoa repens(Permixon?) in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Prostate Cancer, Prostate Dis, 2000,3:195-199
56. Lowe FC, Roberhrborn CG, Robertson C, et al. Metaanalysis of clinical trials of Permixon. J Urol,1998,159,257, A986
57. Lowe FC, Dreikorn K, Borkowski A, et al. Review of recent placebo controlled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate,1998,37, 187-193
58. Breza J, Dzurny O, Borowka A, et al. Efficacy and acceptability of Tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia(BPH):a multiculture trial in central Europe. Curr Med Res Opin,1998,14:127-139
59. Berges RR, Kassen A, Senge T. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol:an 182month followup. BJU Int,2000,85,842-846
60. Klippel KF, Hilti DM. Schipp B for the German BPH-Phytotherapy Study Group. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. Br J Urol,1997,80: 427-432
61. Dreikorn K. In Proceedings of the Fourth International Cousultation on Beinign Prostate Hyperplasia (BPH). Paris,1997,2-5
62.王宏志.癃闭舒胶囊治疗良性前列腺增生疗效观察.中华男科学杂志,2005,11(11)：873
63.陈光晖,刘玉玲,佟继铭.癃必舒胶囊对大鼠实验性前列腺增生的影响.时珍国医国药,2007,18(16)：1362-1363
64.李祥光,鞠大宏,宋竖旗,等.前列舒通对前列腺增生模型大鼠bcl-2表达的影响.中国中西药结合外科杂志,2008,14(2)：141-143
65.张亚强.日本应用汉方药治疗前列腺增生的临床研究.国外医学中医中药分册,2000,22(3)：145-147
66.蒋荣伟,岳宗相,王久源,等.桂枝茯苓加味汤治疗良性前列腺增生症.现代中西医结合杂志,2008,17(9)：1369
67.许国振,崔金涛,严启伟,等.决闭胶囊抗实验性前列腺增生的研究.中成药,2001,23(10)：735-737
68.马清钧,李宏杰,孙曙光,等.乾列安胶囊对肾阳亏虚型前列腺增生症影响的研究.中医药学刊,2003,21(4)：530-531
69.商学军,刘智勇,刘志发,等.福施乐治疗良性前列腺增生的临床研究.中华男科学杂志,2008,14(3)：227-230
70.张凯,杨新宇,张军,等.泽桂癃爽胶囊治疗良性前列腺增生疗效和作用机理的初步研究.中华泌尿外科杂志,2003：24(6)：388-390
[2]Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function:report from the standardisation sub-committee of the International Continence Society.[J]. Urology,2003,61(1):37-49.
[3]Kakizaki H, Matsuura S, Mitsui T, Ameda K, Tanaka H K T. Questionnaire analysis on sex difference in lower urinary tract symptoms.[J]. Urology,2002,59(1): 58-62.
[4]Schatzl G, Temml C, Waldmuller J, Thurridl T, Haidinger G M S. A comparative cross-sectional study of lower urinary tract symptoms in both sexes.[J]. Eur Urol, 2001,40(2):213-219.
[5]Coyne K S, Sexton C C, Thompson C L, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden:results from the Epidemiology of LUTS (EpiLUTS) study.[J]. BJU Int,2009.
[6]Abrams P. LUTS, BPH, BPE, BPO:A Plea for the Logical Use of Correct Terms. [J].Rev Urol,1999,1(1):65.
[7]Andersson K E. Storage and voiding symptoms:pathophysiologic aspects.[J]. Urology,2003,62(5 Suppl 2):3-10.
[8]Spigt M G, Van S C, Van K P, et al. Pathophysiological aspects of bladder dysfunction:a new hypothesis for the prevention of 'prostatic' symptoms.[J]. Med Hypotheses,2004,62(3):448-452.
[9]那彦群.中国泌尿外科疾病诊断治疗指南(2007版)[J].：167-204.
[10]Chute C G, Panser L A, Girman C J, et al. The prevalence of prostatism:a population-based survey of urinary symptoms.[J]. J Urol,1993,150(1):85-89.
[11]Trueman P, Hood Sc, Nayak Us M M. Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK.[J]. BJU Int,1999, 83(4):410-415.
[12]Verhamme K M, Dieleman J P, Bleumink G S, et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care-the Triumph project.[J]. Eur Urol,2002,42(4):323-328.
[13]Horchani A, Binous M Y, Ben H A, et al. [Prevalence of benign prostatic hyperplasia in general practice and practical approach of the Tunisian general practitioner (Prevapt study)][J]. Tunis Med,2007,85(8):619-624.
[14]Berges R. [Epidemiology of benign prostatic syndrome:Associated risks and management data in German men over age 50.][J]. Urologe A,2008,47(2):141-148.
[15]Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia.[J]. Rev Urol,2004,6 Suppl 9:3-10.
[16]Homma Y, Kawabe K, Tsukamoto T, et al. Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the international prostate symptom score[J]. Int J Urol,1997,4(1):40-46.
[17]Mcvary K. Lower urinary tract symptoms and sexual dysfunction:epidemiology and pathophysiology.[J]. BJU Int,2006,97 Suppl 2:23-8445.
[18]蒋先镇；邓素容；何乐业.I-PSS和UFR对女性排尿行为的临床分析。[J].中华泌尿外科杂志,1998,19(4)：233-235.
[19]Irwin D E, Milsom I, Kopp Z, et al. Prevalence, Severity, and Symptom Bother of Lower Urinary Tract Symptoms among Men in the EPIC Study:Impact of Overactive Bladder.[J]. Eur Urol,2009.
[20]Gades N M, Jacobson D J, Girman C J, et al. Prevalence of conditions potentially associated with lower urinary tract symptoms in men.[J]. BJU Int,2005,95(4):549-553.
[1]Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function:report from the Standardisation Sub-committee of the International Continence Society.[J]. Neurourol Urodyn,2002,21(2):167-178.
[2]Berry S J, Coffey D S, Walsh P C, et al. The development of human benign prostatic hyperplasia with age.[J]. J Urol.1984,132(3):474-479.
[3]Chute C G, Panser L A, Girman C J, et al. The prevalence of prostatism:a population-based survey of urinary symptoms.[J]. J Urol,1993,150(1):85-89.
[4]Welch G, Weinger K, Barry M J. Quality-of-life impact of lower urinary tract symptom severity:results from the Health Professionals Follow-up Study.[J]. Urology, 2002,59(2):245-250.
[5]Saigal C S, Joyce G. Economic costs of benign prostatic hyperplasia in the private sector.[J]. J Urol,2005,173(4):1309-1313.
[6]Marquis P, Marrel A. Reproducibility and clinical and concurrent validity of the MSF-4:a four-item male sexual function questionnaire for patients with benign prostatic hyperplasia.[J]. Value Health,2001,4(4):335-343.
[7]Kaplan S A. Reproducibility and clinical and concurrent validity of the MSF-4:a four-item male sexual function questionnaire for patients with benign prostatic hyperplasia.[J]. J Urol.2002,168(4 Pt 1):1661-1662.
[8]Andersson S O, Rashidkhani B, Karlberg L, et al. Prevalence of lower urinary tract symptoms in men aged 45-79 years:a population-based study of 40 000 Swedish men.[J]. BJU Int,2004,94(3):327-331.
[9]Irwin D E, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries:results of the EPIC study.[J]. Eur Urol,2006,50(6):1306-1314,1314-1315.
[10]Coyne K S, Sexton C C, Thompson C L, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden:results from the Epidemiology of LUTS (EpiLUTS) study.[J]. BJU Int,2009.
[11]Vandoninck V, Bemelmans B L, Mazzetta C, et al. The prevalence of urinary incontinence in community-dwelling married women:a matter of definition.[J]. BJU Int,2004,94(9):1291-1295.
[12]Terai A, Matsui Y, Ichioka K, et al. Comparative analysis of lower urinary tract symptoms and bother in both sexes[J]. Urology,2004,63(3):487-491.
[13]Boyle P, Robertson C, Mazzetta C, et al. The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study.[J]. BJU Int,2003,92(4):409-414.
[14]Schatzl G T C W J. A comparative cross-sectional study of lower urinary tract symptoms in both sexes.[J]. Eur Urol,2001,40(2):213-219.
[15]Speakman M J. Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH):More Than Treating Symptoms?[J]. European Urology Supplements.The Future of LUTS/BPH:Management beyond the Prostate,2008, 7(11):680-689.
[16]Seim A, Hoyo C, Ostbye T, et al. The prevalence and correlates of urinary tract symptoms in Norwegian men:the HUNT study.[J]. BJU Int,2005,96(1):88-92.
[17]Perrin P, Marionneau N, Cucherat M, et al. Relationship between lower urinary tract symptoms frequency assessed by the IPSS and bothersomeness (SPI) among men older than 50 years old.[J]. Eur Urol,2005,48(4):601-607.
[18]Barry M J, Fowler F J, O'Leary M P, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.[J]. J Urol,1992,148(5):1549-1557,1564.
[19]Peters T J, Donovan J L, Kay H E, et al. The International Continence Society "Benign Prostatic Hyperplasia" Study:the botherosomeness of urinary symptoms.[J]. J Urol,1997,157(3):885-889.
[20]Barry M J, Fowler F J, O'Leary M P, et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association.[J]. Med Care,1995,33(4 Suppl):S145-S155.
[21]Donovan J L, Abrams P, Peters T J, et al. The ICS-'BPH' Study:the psychometric validity and reliability of the ICSmale questionnaire.[J]. Br J Urol,1996,77(4):554-562.
[22]Irwin D E, Milsom I, Kopp Z, et al. Prevalence, Severity, and Symptom Bother of Lower Urinary Tract Symptoms among Men in the EPIC Study:Impact of Overactive Bladder.[J]. Eur Urol,2009.
[23]Robertson C, Link C L, Onel E, et al. The impact of lower urinary tract symptoms and comorbidities on quality of life:the BACH and UREPIK studies.[J]. BJU Int,2007,99(2):347-354.
[24]Logie J, Clifford G M, Farmer R D. Incidence, prevalence and management of lower urinary tract symptoms in men in the UK.[J]. BJU Int,2005,95(4):557-562.
[25]Garraway W M, Collins G N, Lee R J. High prevalence of benign prostatic hypertrophy in the community.[J]. Lancet,1991,338(8765):469-471.
[26]Verhamme K M, Dieleman J P, Bleumink G S, et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project.[J]. Eur Urol,2002,42(4):323-328.
[27]Clifford G M, Logie J, Fanner R D. How do symptoms indicative of BPH progress in real life practice? The UK experience.[J]. Eur Urol,2000,38 Suppl 1:48-53.
[28]Eckhardt M D, Van V G,Van M H, et al. Prevalence and bothersomeness of lower urinary tract symptoms in benign prostatic hyperplasia and their impact on well-being.[J]. J Urol,2001,166(2):563-568.
[29]Roehrborn C G, Mcconnell J D, Saltzman B, et al. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes.[J]. Eur Urol,2002,42(1):1-6.
[30]Haltbakk J, Hanestad B R, Hunskaar S. Diversity of urinary symptoms in patients tentatively diagnosed with benign prostatic hyperplasia referred to a urologic clinic in Norway.[J]. Scand J Urol Nephrol,2004,38(6):454-461.
[31]Abrams P. Nocturia:the major problem in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (LUTS/BPO)[J]. European Urology Supplements,2005,3(6):8-16.
[32]Chartier-Kastler E, Tubaro A. The Measurement of Nocturia and Its Impact on Quality of Sleep and Quality of Life in LUTS/BPH[J]. European Urology Supplements,2006,5(1):3-11.
[33]Schulman C C, Asplund R, Desgrandchamps F, et al. The Impact of Nocturia on Health Status and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)[J]. European Urology Supplements,2005,4(2):1-8.
[34]Scarpa R M. Lower urinary tract symptoms (LUTS):what are the implications for the patients?[J]. Eur Urol,2001,40((suppl 4)):10-20.
[35]Barry M J. Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia.[J]. Urology,2001,58 (6 Suppl 1):25-32,32.
[36]Li M K, Garcia L, Patron N, et al. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.[J]. BJU Int,2008,101(2):197-202.
[37]Jung J H, Jae S U, Kam S C, et al. Correlation between Lower Urinary Tract Symptoms (LUTS) and Sexual Function in Benign Prostatic Hyperplasia:Impact of Treatment of LUTS on Sexual Function.[J]. J Sex Med,2009.
[1]Azadzoi KM, Tarcan T, Siroky MB, et al. Atherosclerosis-induced chronic ischemia causes bladder fibrosis and noncompliance in the rabbit. J Urol,1999,161 (5):1626.
[2]Guess HA, Arrighi HM, Metter EJ, et al. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate 1990,17: 241-246.
[3]万少平,胡礼泉,刘源.武汉市2811例男性下尿路症状问卷调查.中华泌尿外科杂志,2004,25：585-587.
[4]AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapterl:Diagnosis and treatment recommendations. J Urol,2003,170:530-547.
[5]Rosette JD. Madersbacher S, Alivizatos G, et al. EAU Guidelines on benign prostatic hyperplasia (2004). Chapter3:Assessment,2004,13-31.
[6]杨勇,顾方六.第五届国际良性前列腺增生咨询委员会国际科学委员会推荐意见：老年男性下尿路症状的评估和治疗.中华泌尿外科杂志,2001,22：564.
[7]Roehrborn CG. Accurate determination of prostate size via digital rectal examination and transpectal ultra-sound. Urology,1998,51:19-22.
[8]Resnick M, Ackerman R, Bosch J, et al. Fifth International Consultation on BPH. In:Chatelain C, Denis L, Foo S, et al. Benign Prostatic Hyperplasia. Plymbridge Distributions,2000.169-188.
[9]阙艳红,王学梅.双平面经直肠超声诊断良性前列腺增生的探讨.中华男科学,2005,11(03)：191-191.
[10]Thomas AW, Abrams P. Lower urinary tract symptoms. Benign prostatic obstruction and the overactive bladder. BJU Int,2000,85(Suppl 3):57-68.]
[11]双卫兵,王东文,张旭,等.良性前列腺增生膀胱出口梗阻评判指标分析.中华男科学杂志,2004,10(10)：743.
[12]赵永久,任福金,詹朝辉,等.良性前列腺增生与下尿路症状及急性尿潴留的关系.现代泌尿外科杂志,2004,9(3)：172.
[13]高建平.前列腺疾病与下尿路症状.医学研究生学报,2006,19(2)：97-99.
[14]McConnell JD. Benign prostatic hyperplasia:treatment guidelines and patient classification. Br J Urol,1995,76(Suppl 1):29.
[15]Abrams P, Donovan JL, Rosette JJ, et al. International Continence Society "Benign Prostatic Hyperplasia" Study:background, aims and methodology. Neurourol Urodyn,1997,16(2):79-91.
[16]Rosette JJ, Witjes WP, Schafer W, et al. Relationships between lower urinary tract symptoms and bladder outlet obstruction:results from the ICS-"BPH" study. Neurourol Urodyn,1998,17(2):99-108.
[17]McNeal JE. The zonal anatomy of the prostate. Prostate,1981,2(1):35-49.
[18]Homma Y, Gotch M, Takei M, et al. Predictability of conventional tests for the assessment of bladder outlet obstruction in benign prostatic hyperplasia. Int J Urol, 1998,5(1):61-66.
[19]刘跃新,焦志友,陈山,等.经直肠三维超声在前列腺增生症诊断中的应用.中华泌尿外科杂志,1997,18：490-492.
[20]Steven AK, Alexis ET, Lee BP, et al. Transition zone index as a method of assessing benign prostatic hyperplasia:correlation with symptoms, urine flow and detrusor pressure. J Urol,1995,154(5):1764-1769.
[21]Kurita Y, Masuda H, Terada H, et al. Transition zone index as a risk factor for acute urinary retention in benign prostatic hyperplasia. Urology,1998,51(4): 595-600.
[22]华立新,吴宏飞,眭元庚,等.移行区指数预测良性前列腺增生的临床意义.中华泌尿外科杂志,2003,24(1)：59.
[23]应俊,姚德鸿,任晓敏,等.BPH病人血清fPSA/tPSA比值的临床应用.中华男科学,2001,7(3)：167-169.
[24]Vesely S, Knutson T, Damber JE, et al. Relationship between age, prostate volume, prostate-specific antigen, symptom score and uroflowmetry in men with lower urinary tract symptoms. Scand J Urol Nephrol,2003,37:322-328.
[25]Punglia RS, D'Amico AV, Catalona WJ, et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med,2003,349:335-342.
[26]Roehrborn CG, McConnell JD, Sahzman B, et al. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol,2002,42:1-6.
[27]Laniado ME, Ockrim JL, Marronaro A, et al. Serum prostate specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms. BJU Int,2004,94(9):1283-1286.
[28]Babain RJ, Miyashita H, Evans RB, et al. The distribution of prostate specific antigen in men without clinical or pathological evidence of prostate cancer: relationship to gland volume and age. J Urol,1992,147(3):837-840.
[29]Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA,1993,270(7):860-864.
[30]Haese A, Graefen M, Steuber T, et al. Total and Gleason grade 415 cancer volumes are major contributors of human hallihrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign rostat ic biop sies. J Urol,2003,170(6):2269.
[31]McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperp lasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med,1998,338(9):557-563.
[32]华立新,吴宏飞,眭元庚,等.急性尿潴留对血清前列腺特异性抗原的影响.中华男科学,2002,8(2)：134-135.
[33]Oesterling JE, Rice DC, Glenski WJ, et al. Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate specific antigen concent ration. Urology,1993,42(3):276-282.
[34]顾润国.前列腺炎对血清PSA水平的影响.中华男科学杂志,2001,7(2)：55-57.
[35]高中伟,王明珠,贺大林.血清PSA的影响因素.现代泌尿外科杂志,2001,6(2)：60-62.
[36]Yuan JJ, Coplen DE, Petros JA, et al. Effect s of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J Urol,1992,147:810-814.
[37]Dew T, Coker C, Saadeh F, et al. Influence of investigative and operative procedures on serum prostate specific antigen concentration. Ann Clin Biochem,1999, 36:340-346.
[38]施国伟,何家扬,徐火根.直肠指检对PSA、FPSA影响的研究.临床泌尿外科杂志,2002,17(4)：166-168.
[39]Batislam E, Arik AI, Karakoc A, et al. Effect of transurethral indwelling catheter on serum prostate specific antigen level in benign prostatic hyperplasia. Urology, 1997,49(1):50-54.
[40]Tchergen MB, Song JJ, Strawelerman M, et al. Ejaculation increases the serum prostate specific antigen concentration. Urology,1996,47:511-516.
[41]Douglas TH, Morgan TO, McLeod DG, et al. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients. Cancer,1997,80(1):107-114.
[42]Roehrborm CG, Oesterling JE, Olson PJ, et al. Serial prostate specific antigen measurements in men with clinically BPH during a 12 month placebo-controlled study with terazosin. Urology,1997,50:556.
[43]Stenman UH, Aofthan H. Effect of long term treatment with finasteride on free and total PSA in serum. J Urol,1996,155:698A.
[44]Paus E, Nilsson O, Ole P, et al. Stability of free and total prostate specific antigen in serum from parients with prostate carcinoma and benign hyperplasia. J Urol,1998, 159:1599-1650.
[45]Patel D, White PAE, Milford ward A. A comparison of six commercially assays for total and free prostate specific antigen:the predictive value of the ration of free to total PSA. Br J Urol,2000,85:686-689.
[46]杨勇,吴士良,段继宏,等.良性前列腺增生患者逼尿肌功能的评估和治疗对策.中华外科杂志,2001,39(4)：299.
[47]Elbadawi A, Yalla SV, Rdsnick NM. Structural basis of geriatric voiding dysfunction. Ⅱ. Aging detrusor:normal versus impaired contractility. J Urol,1993, 150:1656-1657.
[48]Nakai H, Yamanishi T, Yasuda K, et al. Correlation between lower urinary tract symptoms and urethral function in benign prostatic hyperplasia. Neurourol Urodyn, 2004,23(7):618.
[49]Hampel C, Dolber PC, Smith MP, et al. Modulation of bladder alphal-adrenergic receptor subtype expression by bladder outlet obstruction. J Urol,2002,167(3):1513.
[50]廖利民.尿流率测定.见：金锡御,宋波,主编.临床尿动力学.北京：人民卫生出版社,2002：88-111.
[51]Smith JC. Some theoretical aspects of urethralresistance. Invest Urol,1964,1: 477-481.
[52]Yoshimura N, Yoshida O, Sasa M, et al. Dopamine D-1 receptor-mediated inhibition of micturition reflex by central dopamine from the substantia nigra. Neurourol Urodyn,1992,11(5):535-545.
[53]Menendez V, Cofan F, Talbot R, et al.Urodynamic cvaluation in simultaneous insulin-dependent diabetes mellitus and end stage renal disease. Clin Urol Urology, 1996,155:2001-2004.
[54]Abrams P, Artibani W, Cardozo L, et al. Reviewing the ICS 2002 terminology report:The ongoing debate. Neurourol Urodyn,2006,25(3):293.
[55]Rowe E, Smith C, Laverick L, et al. A prospective, randomized, placebo controlled, double-blind study of pelvic electromagnetic therapy for the treatment of chronic pelvic pain syndrome with 1 year of followup. J Urol,2005,173(6): 2044-2047.
[56]Shahed AR, Shoskes DA. Correlation of beta-endorphin and prostaglandin E2 levels in prostatic fluid of patients with chronic prostatitis with diagnosis and treatment response. J Urol,2001,166(5):1738-1741.
[57]邓春华,梁宏,梅骅,等.前列腺内尿液返流在慢性前列腺炎发病中的作用.中华泌尿外科杂志,1998,19(6)：288-289.
[58]Persson BE, Ronquist G. Evidence for a mechanistic association between nonbacterial prostatitis and levels of urate and creatinine in expressed prostatic secretion. J Urol,1996,155:958-960.
[1]Trachtenberg J. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression.[J]. BJU Int,2005,95 Suppl 4:6-11.
[2]Emberton M, Anson K. Acute urinary retention in men:an age old problem.[J]. BMJ,1999,318(7188):921-925.
[3]Thomas K, Oades G, Taylor-Hay C, et al. Acute urinary retention:what is the impact on patients' quality of life?[J]. BJU Int,2005,95(1):72-76.
[4]那彦群.中国泌尿外科疾病诊断治疗指南[M].1.北京：人民卫生出版社,2007.167-204.
[5]AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations.[J]. J Urol,2003,170(2 Pt 1):530-547.
[6]Emberton M, Elhilali M, Matzkin H,et al. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily. [J]. Urology,2005,66(2):316-322.
[7]Mcconnell J D, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.[J]. N Engl J Med,1998,338(9):557-563.
[8]Jacobsen S J, Jacobson D J, Girman C J, et al. Natural history of prostatism:risk factors for acute urinary retention.[J]. J Urol,1997,158(2):481-487.
[9]Kumar V, Marr C, Bhuvangiri A, et al. A prospective study of conservatively managed acute urinary retention:prostate size matters.[J]. BJU Int,2000,86(7): 816-819.
[10]Klarskov P, Andersen J T, Asmussen C F, et al. Symptoms and signs predictive of the voiding pattern after acute urinary retention in men.[J]. Scand J Urol Nephrol,1987,21(1):23-28.
[11]Thomas K, Chow K, Kirby R S. Acute urinary retention:a review of the aetiology and management.[J]. Prostate Cancer Prostatic Dis,2004,7(1):32-37.
[12]Kefi A, Koseoglu H, Celebi I, et al. Relation between acute urinary retention, chronic prostatic inflammation and accompanying elevated prostate-specific antigen.[J]. Scand J Urol Nephrol,2006,40(2):155-160.
[13]Roehrborn C G. BPH progression:concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.[J]. BJU Int,2008,101 Suppl 3:17-21.
[14]Spiro L H, Labay G, Orkin L A. Prostatic infarction. Role in acute urinary retention.[J].Urology,1974,3(3):345-347.
[15]Muruganandham K, Dubey D, Kapoor R. Acute urinary retention in benign prostatic hyperplasia:Risk factors and current management.[J]. Indian J Urol,2007, 23(4):347-353.
[16]Thorne M B, Geraci S A. Acute urinary retention in elderly men.[J]. Am J Med,2009,122(9):815-819.
[17]Roehrborn C G, Bruskewitz R, Nickel G C, et al. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group.[J]. Eur Urol,2000,37(5):528-536.
[18]Emberton M, Cornel E B, Bassi P F, et al. Benign prostatic hyperplasia as a progressive disease:a guide to the risk factors and options for medical management. [J]. Int J Clin Pract,2008,62(7):1076-1086.
[19]Marberger M J, Andersen J T, Nickel J C, et al. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials.[J]. Eur Urol, 2000,38(5):563-568.
[20]牛海涛,张勤,赵伟.良性前列腺增生并发急性尿储留的风险因素预测以及临床意义.[J].中华泌尿外科杂志,2007,28(6)：407-410.
[21]Roehrborn C G, Mcconnell J D, Saltzman B, et al. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes.[J]. Eur Urol,2002,42(1):1-6.
[22]Roehrborn C G, Mcconnell J D, Lieber M, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.[J]. Urology,1999,53(3):473-480.
[23]任宝明,何士军,马龙,等.良性前列腺增生症发生急性尿潴留的相关因素分析[J].临床泌尿外科杂志,2007,22(11)：856-857.
[24]Taube M, Gajraj H. Trial without catheter following acute retention of urine.[J]. Br J Urol,1989,63(2):180-182.
[1]Blumenfeld W, Tucci S, Narayan P. Incidental lymphocytic prostatitis. Selective involvement with nonmalignant glands [J]. Am J Surg Pathol,1992,16(10):975-981.
[2]Gerstenbluth RE, Steftel AD, MacLennan GT, et al. Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of Bcl-2 in areas of inflammation[J]. J Urol,2002,167(5):2267-2270.
[3]Collins MM,Meigs JB,Barry MJ,et al.Prevalence and correlates of prostatitis in the health professionals follow-up study cohort [J].J Urol,2002,167(3):1363-1366.
[4]St Sauver JL, Jacobson DJ, McGree ME, et al. Longitudinal association between prostatitis and development of benign prostatic hyperplasia[J]. Urology,2008,71(3): 475-479.
[5]宁夏,时景璞,吴作艳,等.沈阳农村60岁以上人群良性前列腺增生危险因素的病例对照研究[J].中华流行病学杂志,2003,24(4)：276-280.
[6]那彦群.中国泌尿外科疾病诊断治疗指南(2007版)[M].北京：人民卫生出版社,2007：215-219.
[7]Krieger JN, Nyberg LJ, Nickel JC. NIH consensus definition and classification of prostatitis [J]. JAMA,1999,282(3):236-237.
[8]Benson MC. Prostate specific antigen density:a means of distinguishing benign prostatic hyperplasia and prostate cancer [J]. J Urol,1992,147(3):815-816.
[9]华立新,吴宏飞,眭元庚,等.移行区指数作为良性前列腺增生的预测指标[J].南京医科大学学报,2003,23(4)：365-366.
[10]陈业宗,崔强.保列治联合高特灵治疗良性前列腺增生合并慢性前列腺炎的疗效观察[J].医学临床研究,2007,24(5)：818-820.
[11]Theyer G, Kramer G, Assmann I, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia[J]. Lab invest,1992,66 (1): 99-107.
[12]Roehrborn CG, Kaplan SA, Noble WD, et al. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH:results from the MTOPS study[R]. American Urological Association 2005 Moderated Poster, May 24,2005.
[13]夏同礼.良性前列腺增生与前列腺炎的关系值得深入研究[J].中华男科学,2004,10(2)：83-85.
[14]段义星,杨罗艳.前列腺炎和良性前列腺增生症[J].国外医学泌尿系统分册,2004,24(2)：198-202.
[15]Jason PG, Oliver P, Megan D, et al. The role of prolactin in the prostatic inflammatory response to neonatal estrogen[J]. Endocrinology,2003,144(5):2046-2054.
[16]Fromont G, Chene L, Latil A, et al. Molecular profiling of benign prostatic hyperplasia using a large scale real-time reverse transcriptase-polymerase chain reaction approach[J]. J Urol,2004,172(4):1382-1385.
[17]Nickel JC, Roehrborn CG, O'Leary M, et al. Examination of the relationship between symptoms of prostatitis and histological inflammation:baseline data from the REDUCE chemoprevention trial[J]. Urol,2007,178(3 Pt 1):896-900.
[18]Nickel JC. Inflammation and Benign Prostatic Hyperplasia[J]. Urol Clin N Am, 2007,35(1):109-115.
[19]Rowe E, Smith C, Laverick L, et al. A prospective, randomized, placebo controlled, double-blind study of pelvic electromagnetic therapy for the treatment of chronic pelvic pain syndrome with 1 year of followup[J]. J Urol,2005,173(6): 2044-2047.
[20]Shahed AR, Shoskes DA. Correlation of beta-endorphin and prostaglandin E2 levels in prostatic fluid of patients with chronic prostatitis with diagnosis and treatment response[J].J Urol,2001,166(5):1738-1741.
[21]Hussain T, Gupta S, Mukhtar H. Cyclooxygenase and prostate carcinogenesis [J]. Cancer Lett,2003,191(2):125-135.
[22]Anim JT, Udo C, John B. Characterization of inflammatory cells in benign prostatic hyperplasia[J]. Acta Histochem,1998,100(4):439-449.
[23]Kravchick S, Cytron S, Agulansky L, et al. Acute prostatitis in middle-aged men: a prospective study [J]. BJU Int,2004,93(1):93-96.
[24]Mochtar CA, Kiemeney LA, Van Riemsdijk MM, et al. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia[J]. Eur Urol,2003,44(6):695-700.
[25]Kwak C, Ku JH, Kim T, et al. Effect of subclinical prostatic inflammation on serum PSA levels in men with clinically undetectable prostate cancer[J]. Urology, 2003,62:854-859.
[26]Di Silverio F, Gentile V, DeMatteis A, et al. Distributi on of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia:A retrospective analysis [J]. Eur Urol,2003,43:164-175.
[27]Hasui Y, Marutsuka K, Asada Y, et al. Relationship between serum prostate-specific antigen and histological prostatitis in patients with benign prostatic hyperplasia [J].Prostate,1994,25:91-96.
[28]Yaman O, Gogus C, Tulunay O, et al. Increased prostate-specific antigen in subclinical pr ostatitis:The role of aggressiveness and extension of inflammation [J]. Urol Int,2003,71:160-167.
[29]Ozden C, Ozdal OL, Guzel O, et al. The correlation between serum prostate specific antigen levels and asymptomatic inflammatory prostatitis[J]. Int Urol Nephrol, 2007,39:859-863.
[30]Stancik I, Luftenegger W, Klimpfinger M, et al. Effect of NIH-IV prostatitis on free and free-to-total PSA [J]. Eur Urol,2004,46:760-764.
[31]McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxaxosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia[J]. N Engl J Med,2003,349(25):2387-2398.
[32]席志军,宁新荣,郝金瑞,等.前列腺增生症PSA、PSAD与患者的年龄、前列腺体积的关系[J].中华外科杂志,2001,39(2)：170.
[33]Koseoglu DR, Erdemir F, Parlaktas BS. Effect of chronic prostatitis on angiogenic activity and serum prostate specific antigen level in benign prostatic hyperplasia[J]. Kaohsiung J Med Sci,2007,23(8):387-394.
[1]Roehrbom CG, Mc Connell JD. Etiology, pathothysiology, epidemiology and natural history of binign prostatic hyperplasia In:PC Walsh, AB, Retik, ED Vanghan, Jr and AJ Wein. Campbell's Urology. Philadelphia, PA:W.B.Sanndcrs Company, 2002,chapt 38:1297-1330.
[2]Berry MJ, Coffey DS, Walsg PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol,1984,132:474-478.
[3]Gu fl, Xia TL, Kong XT. Preliminary study of the frequency of benign prostatic hyperplasia and prostatic cancer in china. Urology,1994,44:688-691.
[4]Zwergel U, WullichB, Lindenmeir U, et al. Long-term results flowing transurethral resection of the prostate. Eur Urol,1998, (5):476-480.
[5]Saad F, Carrier S, Jolivet-Tremblay M. Comparison of prostatic electrovap-orization and transurethral resection in the treatment of benign prostatic Hypertrophy. Ann Clair,1997,51(8):884-886.
[6]Borborglu PG, Kant CJ, WardJF, et al. Immediate and postoperative complications of transurethral prostatectomy in 1990s. J Urol,1999,162:1307-1310.
[7]Wason JH, Reda DJ, Bruskewitz RC, et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group On Transurethral Resection of the Prostate. New Engl J Med,1995,332:75-79.
[8]Talic RF. Transurethml vaporization-resection of the prostate using Wing cutting electrode:preliminary results of safety and efficacy in the treatment of men with prostatic outflow obstruction. Urology,1999,53(1):106-110.
[9]Cetinkaya ME,Ulnsoy O, adsan H, et al. Comparative early results of transurethral electroresection and transurethral electrovaporizafion in benign prostatic hyperplasia. BJU,1996,78:901-903.
[10]Mebnst WK. Transurethul surgery. In:Walsh PC,Rctok AB, Vaughan ED, Wein AJ, eds. Campbell's urology. Vol 2.8th ed. Philadelphia:Saunders,2003, 1479-1505.
[11]那彦群.中国泌尿外科疾病诊断治疗指南(2007版)[M].北京：人民卫生出版社,2007：215-219.
[12]Benson MC. Prostate specific antigen density:a means of distinguishing benign prostatic hyperplasia and prostate cancer [J]. J Urol,1992,147(3):815-816.
[13]华立新,吴宏飞,眭元庚,等.移行区指数作为良性前列腺增生的预测指标[J].南京医科大学学报,2003,23(4)：365-366.
[14]Mc Cormell JD, Roehrbom CG, Banstita OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. NEengl J Med 2003; 349:2387-2398.
[15]Hon NH, Brathwaite D, Hussain z, et al. A prospective randomized trial comparing conventional transurethral prostate resection with Plasma Kinetic vaporization of the prostate:physiological changes, early complications and long-term followup[J]. J Urol,2006,176(1):205-209.
[16]Ekengren J, Hahn RG. Complications during transurethral vaporization of the prostate. Urology,1996,48(3):424-427.
[17]Cetinlmya ME, Ulusoy O, Adsan H, et al. Comparative early results of transurethral electroreseetion and transurethral electrovaporization in benign prostatic hyperplasia. Br J Urol,1996,78:901-903.
[18]Mcalister WJ, Karim V, Plail RO, et al. Transurethral vaporization of the prostate:is it any better than conventional transurethral resection of the prostate? BJU int,200,91(3):211-214.
[19]Mebust WK, Holtgrewe HL, Coekett ATK, et al. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 anticipating institutions evaluating 3885 patients. J Urol,1989,141:243-247.
[20]周兴,刘春晓,郑少波.经尿道前列腺汽化切割治疗前列腺增生症(附560例报告)[J].中国内镜杂志,2000,6(2)：11-12.
[21]Cetinkaya M, Ulusoy E, Adson O, et al. Comparative early results of transurethral electroresection and transurethral electrovaporisation in benign prostatic hyperplasia[J]. Br Uro l,1996,78:902-903.
[22]毛全宗,荣石,李汉忠,等.良性前列腺增生经尿道前列腺电切术后再次电切手术的临床分析[J].中华医学杂志,2004,84：372-374.
[23]张伦中,李解方,何书华,等.经尿道前列腺等离子双极汽化术与经尿道前列腺单极汽化术治疗高危前列腺增生的临床对比研究[J].中国内镜杂志,2006,4(12)：378-382.
[1]Abrams P. New words for old:lower urinary tract symptoms for 'prostatism'.[J]. BMJ,1994;69:929-30.
[2]Abrams P. LUTS, BPH, BPE, BPO:A Plea for the Logical Use of Correct Terms.[J]. Rev Urol,1999;1(1):65.
[3]Garraway Wm, Collins Gn LR. High prevalence of benign prostatic hypertrophy in the community.[J]. Lancet,1991;338(8765):469-71.
[4]Rm S. Lower urinary tract symptoms (LUTS):what are the implications for the patients?[J]. Eur Urol,2001;40((suppl 4)):10-20.
[5]Kakizaki H, Matsuura S, Mitsui T, Ameda K, Tanaka HKT. Questionnaire analysis on sex difference in lower urinary tract symptoms.[J]. Urology,2002; 59(1): 58-62.
[6]Schatzl G, Temml C, Waldmuller J, Thurridl T, Haidinger GMS. A comparative cross-sectional study of lower urinary tract symptoms in both sexes.[J]. Eur Urol,2001;40(2):213-19.
[7]Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia.[J]. Rev Urol,2004;6 Suppl 9:3-10.
[8]Elbadawi A, Diokno Ac MR. The aging bladder:Morphology and urodynamics. [J]. World J Urol,1998;16((suppl 1)):10-34.
[9]Fultz Nh HA. Epidemiology of urinary symptoms in the geriatric population.[J]. Urol Clin North Am,1996;23(1-10).
[10]Jg M. The prostate gland:morphology and pathobiology.[J]. Monogr Urol.,1983;4:3-33.
[11]Berry Sj, Coffey Ds, Walsh Pc E L. The development of human benign prostatic hyperplasia with age.[J]. J Urol.1984 Sep;132(3):474-9,1984;132(3):474-79.
[12]Jepsen Jv BR. Office evaluation of men with lower urinary tract symptoms.[J]. Urol Clin North Am.,1998;25(4):545-54.
[13]C C. Clinical study of benign prostatic disease, current concepts and future prospects:randomized controlled trials versus real life practice.[J]. Curr Opin Urol.,2003;13(1):1-5.
[14]Berry S J, Coffey D S, Walsh P C, et al. The development of human benign prostatic hyperplasia with age[J]. J Urol,1984; 132(3):474-79.
[15]Barry M J, Fowler F J, Bin L, et al. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists.[J]. J Urol,1997;157(1):10-45.
[16]Meigs J B, Mohr B, Barry M J, et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men.[J]. J Clin Epidemiol,2001;54(9):935-44.
[17]Trueman P, Hood Sc, Nayak Us M M. Prevalence of lower urinary tract symptoms and self-reported diagnosed'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK.[J]. BJU Int,1999;83(4):410-15.
[18]Verhamme K M, Dieleman J P, Bleumink G S, et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project.[J]. Eur Urol,2002;42(4):323-28.
[19]Horchani A, Binous MY, Ben HA, et al. [Prevalence of benign prostatic hyperplasia in general practice and practical approach of the Tunisian general practitioner (Prevapt study)][J]. Tunis Med,2007;85(8):619-24.
[20]Berges R. [Epidemiology of benign prostatic syndrome:Associated risks and management data in German men over age 50.][J]. Urologe A,2008;47(2):141-48.
[21]Homma Y, Kawabe K, Tsukamoto T, et al. Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the international prostate symptom score[J]. Int J Urol,1997;4(1):40-46.
[22]Lowe F C, Batista J, Berges R, et al. Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion.[J]. Prostate Cancer Prostatic Dis,2005; 8(3): 206-9.
[23]Fitzpatric JM. The natural history of benign prostatic hyperplasia.[J]. BJU Int, 2006,97(Suppl 2):3-6.
[24]Jacobsen S J, Girman C J, Lieber M M. Natural history of benign prostatic hyperplasia.[J]. Urology,2001;58(6 Suppl 1):5-16.
[25]Roehrborn C G. BPH progression:concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.[J]. BJU Int.,2008; 101 (Suppl 3):17-21.
[26]Emberton M, Zinner N, Michel M C, et al. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia:therapeutic options for the man at risk.[J]. BJU Int,2007;100(2):249-53.
[27]Fong Yk, Milani S D B. Natural history and clinical predictors of clinical progression in benign prostatic hyperplasia.[J]. Curr Opin Urol.,2005;15(1):35-38.
[28]Gup D I, Shapiro E, Baumann M, et al. Contractile properties of human prostate adenomas and the development of infravesical obstruction.[J]. Prostate,1989,15(2): 105-14.
[29]Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia.[J]. N Engl J Med.,1987;317(10):599-4.
[30]Kutikov A, Guzzo T J, Malkowicz S B. Clinical approach to the prostate:an update.[J]. Radiol Clin North Am,2006;44(5):649-63.
[31]Lepor H, Tang R, Kobayashi S, et al. Localization of the alpha 1A-adrenoceptor in the human prostate.[J]. J Urol,1995;154(6):2096-99.
[32]Lepor H, Tang R, Shapiro E. The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle.[J]. Prostate,1993;22(4):301-7.
[33]Walden P D, Gerardi C, Lepor H. Localization and expression of the alphalA-1, alphalB and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate.[J]. J Urol,1999;161(2):635-40.
[34]Levin R M, Levin S S, Zhao Y, et al. Cellular and molecular aspects of bladder hypertrophy.[J]. Eur Urol,1997;32 Suppl 1:15-21.
[35]Thomas A W, Abrams P. Lower urinary tract symptoms, benign prostatic obstruction and the overactive bladder.[J]. BJU Int,2000;85 Suppl 3:57-1.
[36]Knutson T, Edlund C, Fall M, et al. BPH with coexisting overactive bladder dysfunction--an everyday urological dilemma.[J]. Neurourol Urodyn,2001,20(3): 237-47.
[37]Andersson K E. Storage and voiding symptoms:pathophysiologic aspects.[J]. Urology,2003;62(5 Suppl 2):3-10.
[38]Levin R M, Haugaard N, O C L, et al. Obstructive response of human bladder to BPH vs. rabbit bladder response to partial outlet obstruction:a direct comparison.[J]. Neurourol Urodyn,2000; 19(5):609-29.
[39]Nevel-mcgarvey C A, Levin R M, Haugaard N, et al. Mitochondrial involvement in bladder function and dysfunction.[J]. Mol Cell Biochem,1999,194 (1-2):1-15.
[40]Steers W D, Clemow D B, Persson K, et al. The spontaneously hypertensive rat: insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males.[J]. Exp Physiol,1999;84(1):137-47.
[41]Chai T C, Andersson K E, Tuttle J B, et al. Altered neural control of micturition in the aged F344 rat.[J]. Urol Res,2000;28(5):348-54.
[42]Isaacs J T. Etiology of benign prostatic hyperplasia. [J]. Eur Urol,1994;25 Suppl 1:6-9.
[43]Colombel M, Vacherot F, Diez S G, et al. Zonal variation of apoptosis and proliferation in the normal prostate and in benign prostatic hyperplasia.[J]. Br J Urol,1998;82(3):380-85.
[44]Marcelli M, Cunningham G R. Hormonal signaling in prostatic hyperplasia and neoplasia.[J]. J Clin Endocrinol Metab,1999;84(10):3463-68.
[45]Mcconnell J D. Benign prostatic hyperplasia. Hormonal treatment.[J]. Urol Clin North Am,1995;22(2):387-0.
[46]Roberts R O, Jacobson D J, Rhodes T, et al. Serum sex hormones and measures of benign prostatic hyperplasia. [J]. Prostate,2004;61 (2):124-31.
[47]Prins G S, Korach K S. The role of estrogens and estrogen receptors in normal prostate growth and disease.[J]. Steroids,2008;73(3):233-44.
[48]Smith P, Rhodes N P, Ke Y, et al. Relationship between upregulated oestrogen receptors and expression of growth factors in cultured, human, prostatic stromal cells exposed to estradiol or dihydrotestosterone.[J]. Prostate Cancer Prostatic Dis,2004;7(1):57-62.
[49]Partin A W, Oesterling J E, Epstein J I, et al. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. [J]. J Urol,1991;145(2):405-9.
[50]Roberts R O, Jacobson D J, Rhodes T, et al. Serum sex hormones and measures of benign prostatic hyperplasia.[J]. Prostate,2004;61(2):124-31.
[51]Nickel J C. Inflammation and benign prostatic hyperplasia.[J]. Urol Clin North Am,2008;35(1):109-15.
[52]Mishra V C, Allen D J, Nicolaou C, et al. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia?[J]. BJU Int,2007;100(2):327-31.
[53]Wang L, Yang J R, Yang L Y, et al. [Expression of Ki-67,Bcl-2,Bax and caspase-3 in benign prostatic hyperplasia combined with prostatitis and their significances.][J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban,2008;33(3):222-26.
[54]Penna G, Mondaini N, Amuchastegui S, et al. Seminal plasma cytokines and chemokines in prostate inflammation:interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia.[J]. Eur Urol,2007;51(2):524-33.
[55]Nickel J C. Inflammation and benign prostatic hyperplasia.[J]. Urol Clin North Am,2008;35(1):109-15.
[56]Steiner G, Gessl A, Kramer G, et al. Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia.[J]. J Urol,1994;151(2):480-84.
[57]Kramer G, Steiner G E, Handisurya A, et al. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation.[J]. Prostate,2002;52(1):43-58.
[58]Steiner G E, Stix U, Handisurya A, et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue.[J]. Lab Invest,2003;83(8):1131-46.
[59]Rohrmann S, De M A, Smit E, et al. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES Ⅲ).[J]. Prostate,2005;62(1):27-33.
[60]Konig J E, Senge T, Allhoff E P, et al. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer.[J]. Prostate,2004;58(2):121-29.
[61]Castro P, Xia C, Gomez L, et al. Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia.[J]. Prostate,2004;60(2):153-59.
[62]Taoka R, Tsukuda F, Ishikawa M, et al. Association of prostatic inflammation with down-regulation of macrophage inhibitory cytokine-1 gene in symptomatic benign prostatic hyperplasia.[J]. J Urol,2004;171(6 Pt 1):2330-35.
[63]Yun A J, Doux J D. Opening the floodgates:benign prostatic hyperplasia may represent another disease in the compendium of ailments caused by the global sympathetic bias that emerges with aging.[J]. Med Hypotheses,2006;67(2):392-94.
[64]Mcvary K T, Rademaker A, Lloyd G L, et al. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.[J]. J Urol,2005; 174(4 Pt 1):1327-33.
[65]Partin J V, Anglin I E, Kyprianou N. Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction.[J]. Br J Cancer,2003;88(10):1615-21.
[66]Dinh D T, Frauman A G, Somers G R, et al. Evidence for activation of the renin-angiotensin system in the human prostate:increased angiotensin II and reduced AT(1) receptor expression in benign prostatic hyperplasia. [J]. J Pathol,2002; 196(2): 213-19.
[67]Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?[J]. Eur Urol,2007;51(5):1202-16.
[68]Yokota T, Honda K, Tsuruya Y, et al. Functional and anatomical effects of hormonally induced experimental prostate growth:a urodynamic model of benign prostatic hyperplasia (BPH) in the beagle.[J]. Prostate,2004;58(2):156-63.
[69]Olapade-olaopa E O, Moscatello D K, Mackay E H, et al. A variant epidermal growth factor receptor protein is similarly expressed in benign hyperplastic and carcinomatous prostatic tissues in black and white men.[J]. West Afr J Med,2007, 26(1):42-47.
[70]Eaton C L. Aetiology and pathogenesis of benign prostatic hyperplasia. [J]. Curr Opin Urol,2003;13(1):7-10.
[71]Lee K L, Peehl D M. Molecular and cellular pathogenesis of benign prostatic hyperplasia.[J]. J Urol,2004; 172(5 Pt 1):1784-91.
[72]Mirone V, Imbimbo C, Longo N, et al. The detrusor muscle:an innocent victim of bladder outlet obstruction. [J]. Eur Urol,2007;51(1):57-66.
[73]Levin R, Chichester P, Levin S, et al. Role of angiogenesis in bladder response to partial outlet obstruction.[J]. Scand J Urol Nephrol Suppl,2004(215):37-47.
[74]Pearson J D, Lei H H, Beaty T H, et al. Familial aggregation of bothersome benign prostatic hyperplasia symptoms.[J]. Urology,2003;61(4):781-85.
[75]Mcvary K. Lower urinary tract symptoms and sexual dysfunction:epidemiology and pathophysiology.[J]. BJU Int,2006;97 Suppl 2:23-45.
[76]Ikuerowo S O, Akindiji Y O, Akinoso O A, et al. Association between erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia in Nigerian men.[J]. Urol Int,2008;80(3):296-99.
[77]Braun M H, Sommer F, Haupt G, et al. Lower urinary tract symptoms and erectile dysfunction:co-morbidity or typical "Aging Male" symptoms? Results of the "Cologne Male Survey".[J]. Eur Urol,2003;44(5):588-94.
[78]Seim A, Hoyo C, Ostbye T, et al. The prevalence and correlates of urinary tract symptoms in Norwegian men:the HUNT study.[J]. BJU Int,2005;96(1):88-92.
[79]Holden C A, Jolley D J, Mclachlan R I, et al. Men in Australia Telephone Survey (MATeS):predictors of men's help-seeking behaviour for reproductive health disorders.[J]. Med J Aust,2006;185(8):418-22.
[80]Ponholzer A, Temml C, Mock K, et al. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire.[J]. Eur Urol,2005,47(1): 80-56.
[81]Li M K, Garcia L, Patron N, et al. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.[J]. BJU Int,2008;101(2):197-2.
[82]Ikuerowo S O, Akindiji Y O, Akinoso O A, et al. Association between erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia in Nigerian men.[J]. Urol Int,2008;80(3):296-99.
[83]Ozayar A, Zumrutbas A E, Yaman O. The relationship between lower urinary tract symptoms (LUTS), diagnostic indicators of benign prostatic hyperplasia (BPH), and erectile dysfunction in patients with moderate to severely symptomatic BPH.[J]. Int Urol Nephrol,2008.
[84]Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction:the multinational survey of the aging male (MSAM-7).[J]. Eur Urol,2003;44(6):637-49.
[85]Chang S, Hypolite J A, Zderic S A, et al. Increased corpus cavernosum smooth muscle tone associated with partial bladder outlet obstruction is mediated via Rho-kinase.[J]. Am J Physiol Regul Integr Comp Physiol,2005;289(4):1124-30.
[86]Khan M A, Thompson C S, Dashwood M R, et al. Endothelin-1 and nitric oxide in the pathogenesis of urinary tract disorders secondary to bladder outlet obstruction.[J]. Curr Vasc Pharmacol,2003;1(1):27-31.
[87]Lowe F C. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia:sexual function.[J]. BJU Int,2005;95 Suppl 4:12-18.
[88]Carson C C. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia:treatments of lower urinary tract symptoms, erectile dysfunction, or both?[J]. BJU Int,2006;97 Suppl 2:39-45.
[89]Demir O, Murat N, Asian G, et al. Effect of doxazosin with and without rho-kinase inhibitor on human corpus cavernosum smooth muscle in the presence of bladder outlet obstruction.[J]. J Urol,2006;175(6):2345-49.
[90]Gonzalez R R, Kaplan S A. Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.[J]. Expert Opin Drug Metab Toxicol,2006;2(4):609-17.
[91]Mcvary K T, Kaufman J, Young J M, et al. Sildenafil citrate improves erectile function:a randomised double-blind trial with open-label extension.[J]. Int J Clin Pract,2007;61(11):1843-49.
[92]Kaplan S A, Gonzalez R R, Te A E. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.[J]. Eur Urol,2007;51 (6):1717-23.
[93]Stief C G, Porst H, Neuser D, et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.[J]. Eur Urol,2008; 53(6): 1236-44.
[94]Djavan B. Guidelines on benign prostatic hyperplasia:where do we stand in the new millennium?[J]. Curr Urol Rep.2002 Apr;3(2):91-2.,2002;3(2):91-92.
[95]那彦群.中国泌尿外科疾病诊断治疗指南[M].1 ed.北京：人民卫生出版社,2007：167-4.
[96]Jepsen J V, Bruskewitz R C. Office evaluation of men with lower urinary tract symptoms.[J]. Urol Clin North Am,1998;25(4):545-54.
[97]Barry M J. Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia.[J]. Urology,2001;58(6 Suppl 1):25-32.
[98]Weiss J P, Blaivas J G, Tash A J, et al. Development and validation of a new treatment outcome score for men with LUTS.[J]. Neurourol Urodyn,2004; 23(2): 88-93.
[99]Speakman M J, Kirby R S, Joyce A, et al. Guideline for the primary care management of male lower urinary tract symptoms.[J]. BJU Int,2004;93(7):985-90.
[100]Barry M J, Fowler F J, O L M, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.[J]. J Urol,1992;148(5):1549-64.
[101]Donovan J L. Use of symptom questionnaires in the assessment and follow-up of men with benign prostatic disease.[J]. Curr Opin Urol,1999;9(1):3-7.
[102]Peters T J, Donovan J L, Kay H E, et al. The International Continence Society "Benign Prostatic Hyperplasia" Study:the botherosomeness of urinary symptoms.[J]. J Urol,1997;157(3):885-89.
[103]Netto N R, De L M, Netto M R, et al. Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting.[J]. Urology,1999;53(2):314-16.
[104]Spatafora S, Conti G, Perachino M, Casarico A, Mazzi G P G, A I B G C. Evidence-based guidelines for the management of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy:updated summary.[J]. Curr Med Res Opin.,2007;23(7):1715-32.
[105]Harkaway R C, Issa M M. Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia. [J]. Prostate Cancer Prostatic Dis,2006; 9(3): 204-14.
[106]Price D. Potential mechanisms of action of superselective alpha(1)-adrenoceptor antagonists.[J]. Eur Urol,2001;40 Suppl 4:5-11.
[107]Levy A, Samraj G P. Benign prostatic hyperplasia:when to'watch and wait,' when and how to treat.[J]. Cleve Clin J Med,2007;74 Suppl 3:15-20.
[108]Roehrborn C G. Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia:achievements and limitations.[J]. Rev Urol,2008;10(1):14-25.
[109]Nix J W, Carson C C. Medical management of benign prostatic hypertrophy. [J]. Can J Urol,2007;14 Suppl 1:53-57.
[110]Stief C G, Porst H, Neuser D, et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.[J]. Eur Urol,2008; 53(6):1236-44.
[111]Kaplan Sa, Roehrborn Cg, Chancellor M, Carlsson M, Bavendam T G Z. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder:effects on urinary symptoms assessed by the International Prostate Symptom Score.[J]. BJU Int.,2008.
[112]Andersson K E. LUTS treatment:future treatment options.[J]. Neurourol Urodyn,2007;26(6 Suppl):934-47.
[113]Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia.[J]. Rev Urol,2007;9(4):181-90.
[114]Mcvary K T. A review of combination therapy in patients with benign prostatic hyperplasia.[J]. Clin Ther,2007;29(3):387-98.
[115]Gallegos P J, Frazee L A. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.[J]. Pharmacotherapy,2008; 28 (3):356-65.
[116]Blake-james B T, Rashidian A, Ikeda Y, et al. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia:a systematic review and meta-analysis.[J]. BJU Int,2007;99(1):85-96.
[117]Andersson K E, Uckert S, Stief C, et al. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS.[J]. Neurourol Urodyn,2007;26(6 Suppl):928-33.
[118]Gur S, Kadowitz P J, Hellstrom W J. Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction:implications for sexual dysfunction.[J].Drugs,2008;68(2):209-29.
1. Guess HA, ArrighiHM, MetterEJ, et al. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate 1990; 17: 241-246
2.万少平,胡礼泉,刘源.武汉市2811例男性下尿路症状问卷调查.中华泌尿外科杂志,2004,25：585-587
3. Walsh PC, Hutehins GM, Ewing LL. Tissue content of dihydrotestosterone in human prostatic hyperplasis is not supranormal. J Clin Invest,1983,72:1772-1777
4. Steers WD.5 alpha-reductase activity in the Porsate. Uorlogy,2001,58:17-24
5. McConell JD, Wilson JD, Gerogre FW, et al. Finasteirde, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign Prostatic hyperplasia. J Clin Endocrinal Metav,1992,74:505-508
6. Nomran RW, Coakes KE, Wright AS. Meatbolism in men receiving finasteride before prostatectomy. J Urol,1993,150:1736-173
7. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med,1992,327:1185-1191
8. MeConnell JD, Bruskewitz MD, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med,1998,338:557-563
9. McCoenll JD, Reginald B, Whlsh P, et al. The effect of finasteirde on the risk of acute urinary retention and he need for surgical treatment among men with benign prostatic hyperplasia. N Engle J Med,1998,338:557-563
10. Lowe FC, MeConnell JD, Hudson PB, et al. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology,2003,61:791-796
11. Kaplan S, Holtgrewe H, Bruskewitz R, et al. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology,2001,57:1073-1077
12. Mcconnde JD. Finasteride, An inbibiter of 5α-redctase suppresses prostatic, dihydrotestosterone in men with benign Prostatic hyperplasia. J Clin Endocrinol Metab,1992:74:505
13. Herbert L. The efficacy of terazosin finasterideor both in benign prostatic hyperplasia. N Engl Med,1996,335(8):533
14.酒井英树.前列腺肥大的内分泌治疗.日本医学介绍,1997,18(10)：470
15. Andriole G, Bostwick D, Brawley O, et al. Chemoprevention of prostate cancer in man at high risk:rationale and design of the reduction by dutasteride of prostate ca ncer events (REDUCE) trial. J Urol,2004,172:1314-1317
16. Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benigh prostatic hyperplasia. Urology,2002,60:434-441
17. O'leary MP, Roehrborn C, Andriole G, et al. Improvements in benigh prostatic hyperplasia specific quality of life with dutasteride, the novel dual 5a-reductase inhibitor. BJU Inter,2003,92:262-266
18. Chapple CR. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms:an over view for the Practising clinician. BJU Int,2004,94: 738-744
19. Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology,2004,63: 709-715
20. Lepor H, Tang R, Shapiro E. The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle. Prostate,1993,22(4):301-307.
21. Walden PD, Gerardi C, Lepor H. Localization and expression of the alphalA-1 alpha1B, alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. J Urol,1999,161(2):635-640
22. Muramatsu I, Taniguchi T, Okada K. Tamsulosin:alphal adrenoceptor subtype-selectivity and comparison with terazosin. Jpn J Pharmacol,1998,78(3): 331-335
23. Kyprianou N, Litvak JP, Borkowski A, et al. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol,1998,159(6):1810-1815
24. Taniguchi N, Ukai Y, Tanaka T, et al. Identification of alpha 1-a-drenoceptor subtypes in the human prostatic urethra. Naunyn Schmiedebergs Arch Pharmacol, 1997,355(3):412-416
25. Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha-1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol,2003,170(2 Pt 1):649-653
26. Yamamoto T, Ghosh R, De Groat WC, et al. Facilitation of transmitter release in the urinary bladders of neonatal and adult rats via alphal-a-drenoceptors. Eur J Pharmacol,2001,414(1):31-35
27. Yashiyama M, De Groat WC. Role of spinal alpha1-adrenoceptor subtypes in the bladder reflex in anesthetized rats. Am J Physiol Regul Integr Comp Physiol, 2001,280(5):R1414-1419
28. Chapple CR. Pharmacotherapy for benign prostatic hyperplasia the potential for al-adrenoceptor subtype specific blockade. Br J Urol,1998,81:34-47
29. Hayashi T, Sakai Y, Saito K, et al. A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia. Hinyokika Kiyo,2002,48(1):7-11
30. Lepor H, Jones K, Williford W. The mechanism of adverse events associated with terazosin:an analysis of the Veterans Affairs cooperative study. J Urol,2000, 163(4):1134-1137
31.Iepor H, Jones K, Williford W. The mechanism of adverse events associated with terazosin:an analysis of the Veterans Affairse operative study. J Urol,2000,163: 1134-1137
32. Michel MC, Flannery MT, Narayan P. Worldwide experience with alfuzosin and tamsulosin. Urology,2001,58(4):508-516
33. Lepor H, WillifodrE, KontuirM, et al. The efficacy of terazosin, finasterider, or both in benign Prostatic hyperplasia.Veterans Afeirs Cooperative Studies Benign Prostatic Hyperplasia Study GrouP. N Engl J Med,1996,335(8):533-539
34. Bautisatom, Kusek JW, Nbyegr LM, et al. Study design of the medical therapy of prostatic symptoms (MTOP) trail. Control Clin Trail,2003,24:224-243
35. McConell JD, Roellrborn CG, Batuista OM, et al. The long-term effect of coxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med,2003,349:2387-2398
36. Athanasopoulos A, Gyftopoulos K, Giannitasa K, et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction:a prospective, randomized, controlled study. Urology,2003,169(60):2253-2256
37. Yarker Y, Goa KL, Fitton A. Oxybutytnin:A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drug Aging, 1995,6(3):243-262
38. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder:results of the object study. Mayo Clin Proc,2001,76(4): 358-3613
39. Davila GW, Daugherty CA,Sanders SW. A shortterm, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate realease oral oxybutynin treatment of patents with urge urinary incontinence. J Urol,2001,166(1):140-145
40. Nilvebrant L, Andersson KE, Gillberg PG, et al. Tolterodine a new bladder-selective antimuscarinic agent. Eur J Pharmacol,1997; 327:195-207
41.吴士良,杨勇,薛兆英,等.新型抗胆碱能药物托特罗定治疗膀胱过度活动症的临床研究.中华泌尿外科杂志,2001；22(4)：217-219
42. Postlind H, Danielson A, Lindgren A, et al. Tolterodine, a novel muscarinic receptor antagonist, ismetabolized by cytochromes P450 2D6 and 3A4 in human liver microsomes. Drug Metab Dispos,1998,26(4):289-293
43. Brynne N, Aperia B, AbergWistedt A, et al. Inhibition of tolterodine metabolism by fluoxetine w ith minor change in antimuscarinic activity. Eur J Clin Pharmacol, 1997,52 Suppl:A 1301
44. Chancellor M, Freedaman S, Mitcheson HD. Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clin Drug Invest,2000,19(2):83-91
45. Messelink EJ. Treatment of the overactive bladder with tolterodine, a new muscarinic receptor antagonist. BJU International,1999,83 Suppl2:48-52
46. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder:a pooled analysis. Urology,1997,50 (6A Suppl):90-96
47. Stohrer M, Bauer P, Giannetti BM. Effect of t rospium chloride on urodynamic parameters in patient s with detrusor hyperreffexia due to spinal cord injuries. Urol Int,1991-ncbi. nlm. nih. gov
48. Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol,2004,172(5Pt1):1919-1924
49.罗景慧,杨迎暴.曲司氯铵-治疗伴有急迫性症状的膀胱过度活动症的新药.中国新药与临床杂志,2006,25(6)：466-469
50. Schladitzkeil G, Spahn H, Mutschler E. Determination of t he bioavailability of the quaternary compound trospiu chloride in man from urinary excretion data. Arzneimittelforsch,1986,6(6):984-987
51. Sandage B, Najarian N, Lasseter K. The effect of hepatic disease on the pharmacokinetics of t rospium chloride [C]//Program and Abstract s of the Annuel Metting of the International Continence Society. Paris, France:Indevus Pharmaceuticals Inc,2004:584
52. Stohrer M, Bauer P, Glannetti BM, et al. Effect of trospium chloride on urodynamic parameters in patient s wit h det rusor hyperreflexia due to spinal cord injuries. Amulticent re placebo2cont rolles double-blind trial. Urol Int,1991,47(3): 138-143
53. Todorova A, Vendeheid-Guth B, Dimofel W. Tolterodine, trospium chloride and oxybynin on t he central nervous system. J Clin Pharmacol,2001,40(16):636-644
54. Gerber GS. Saw palmetto for the treatment of men with lower urinary tract symptoms. J Urol,2000,163:1408-1412
55. Al-Shukri, Deschaseaux P, Kuzmin IV, et al. Early urodynamic effects of lipidosterolic extract of Serenoa repens(Permixon?) in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Prostate Cancer, Prostate Dis, 2000,3:195-199
56. Lowe FC, Roberhrborn CG, Robertson C, et al. Metaanalysis of clinical trials of Permixon. J Urol,1998,159,257, A986
57. Lowe FC, Dreikorn K, Borkowski A, et al. Review of recent placebo controlled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate,1998,37, 187-193
58. Breza J, Dzurny O, Borowka A, et al. Efficacy and acceptability of Tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia(BPH):a multiculture trial in central Europe. Curr Med Res Opin,1998,14:127-139
59. Berges RR, Kassen A, Senge T. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol:an 182month followup. BJU Int,2000,85,842-846
60. Klippel KF, Hilti DM. Schipp B for the German BPH-Phytotherapy Study Group. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. Br J Urol,1997,80: 427-432
61. Dreikorn K. In Proceedings of the Fourth International Cousultation on Beinign Prostate Hyperplasia (BPH). Paris,1997,2-5
62.王宏志.癃闭舒胶囊治疗良性前列腺增生疗效观察.中华男科学杂志,2005,11(11)：873
63.陈光晖,刘玉玲,佟继铭.癃必舒胶囊对大鼠实验性前列腺增生的影响.时珍国医国药,2007,18(16)：1362-1363
64.李祥光,鞠大宏,宋竖旗,等.前列舒通对前列腺增生模型大鼠bcl-2表达的影响.中国中西药结合外科杂志,2008,14(2)：141-143
65.张亚强.日本应用汉方药治疗前列腺增生的临床研究.国外医学中医中药分册,2000,22(3)：145-147
66.蒋荣伟,岳宗相,王久源,等.桂枝茯苓加味汤治疗良性前列腺增生症.现代中西医结合杂志,2008,17(9)：1369
67.许国振,崔金涛,严启伟,等.决闭胶囊抗实验性前列腺增生的研究.中成药,2001,23(10)：735-737
68.马清钧,李宏杰,孙曙光,等.乾列安胶囊对肾阳亏虚型前列腺增生症影响的研究.中医药学刊,2003,21(4)：530-531
69.商学军,刘智勇,刘志发,等.福施乐治疗良性前列腺增生的临床研究.中华男科学杂志,2008,14(3)：227-230
70.张凯,杨新宇,张军,等.泽桂癃爽胶囊治疗良性前列腺增生疗效和作用机理的初步研究.中华泌尿外科杂志,2003：24(6)：388-390